

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/59092 A2

(51) International Patent Classification⁷: C12N 15/00

Way, Baltimore, MA 21208 (US). KINZLER, Kenneth, W. [US/US]; 1403 Halkirk Way, BelAir, MD 21015 (US).

(21) International Application Number: PCT/US01/04339

(22) International Filing Date: 12 February 2001 (12.02.2001)

(74) Agents: KAGAN, Sarah, A. et al.: Banner & Witcoff, Ltd., Eleven floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/181,929 11 February 2000 (11.02.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 60/181,929 (CON)
Filed on 11 February 2000 (11.02.2000)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): THE JOHNS HOPKINS UNIVERSITY [US/US]; 111 Market Place, Suite 906, Baltimore, MD 21202 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): NICOLAIDES, Nicholas, C. [US/US]; 4 Cider Mill Court, Boothwyn, PA 19061 (US). SASS, Philip, M. [US/US]; 1903 Blackhawk Circle, Audubon, PA 19403 (US). GRASSO, Luigi [US/US]; 834 Chestnut Street, Apt. #816, Philadelphia, PA 19107 (US). VOGELSTEIN, Bert [US/US]; 3700 Breton

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/59092 A2

(54) Title: METHODS FOR GENERATING HYPERMUTABLE MICROBES

(57) Abstract: Bacteria are manipulated to create desirable output traits using dominant negative alleles of mismatch repair proteins. Enhanced hypermutation is achieved by combination of mismatch repair deficiency and exogenously applied mutagens. Stable bacteria containing desirable output traits are obtained by restoring mismatch repair activity to the bacteria.

METHODS FOR GENERATING HYPERMUTABLE MICROBES

- 5 This application claims the benefit of provisional application S.N. 60/181,929 filed February 11, 2000.

FIELD OF THE INVENTION

- 10 The invention is related to the area of mismatch repair genes. In particular it is related to the field of *in situ* mutagenesis of single celled organisms.

BACKGROUND OF THE INVENTION

- 15 Within the past four years, the genetic cause of the Hereditary Nonpolyposis Colorectal Cancer Syndrome (HNPCC), also known as Lynch syndrome II, has been ascertained for the majority of kindred's affected with the disease (14). The molecular basis of HNPCC involves genetic instability resulting from defective mismatch repair (MMR). Several genes have been identified in humans that encode for proteins and
- 20 appear to participate in the MMR process, including the *mutS* homologs *GTBP*, *hMSH2*, and *hMSH3* and the *mutL* homologs *hMLH1*, *hMLH3*, *hPMS1*, and *hPMS2* (4,9,11,17,19,22,24,38). Germline mutations in four of these genes (*hMSH2*, *hMLH1*, *hPMS1*, and *hPMS2*) have been identified in HNPCC kindred's (13). Though the mutator defect that arises from the
- 25 MMR deficiency can affect any DNA sequence, microsatellite sequences are particularly sensitive to MMR abnormalities (14, 25, 27, 29). Microsatellite instability (MI) is therefore a useful indicator of defective MMR. In addition to its occurrence in virtually all tumors arising in HNPCC patients, MI is found in a small fraction of sporadic tumors with
- 30 distinctive molecular and phenotypic properties (13).

HNPCC is inherited in an autosomal dominant fashion, so that the normal cells of affected family members contain one mutant allele of the

relevant MMR gene (inherited from an affected parent) and one wild-type allele (inherited from the unaffected parent). During the early stages of tumor development, however, the wild-type allele is inactivated through a somatic mutation, leaving the cell with no functional MMR gene and
5 resulting in a profound defect in MMR activity. Because a somatic mutation in addition to a germ-line mutation is required to generate defective MMR in the tumor cells, this mechanism is generally referred to as one involving two hits, analogous to the biallelic inactivation of tumor suppressor genes that initiate other hereditary cancers. In line with this
10 two-hit mechanism, the non-neoplastic cells of HNPCC patients generally retain near normal levels of MMR activity due to the presence of the wild-type allele (11, 13, 24). In addition, similar findings are observed in other diploid organisms (2, 5, 8).

The ability to alter signal transduction pathways by manipulation of
15 a gene product's function, either by over-expression of the wild type protein or a fragment thereof, or by introduction of mutations into specific protein domains of the protein, the so-called dominant-negative inhibitory mutant, were described over a decade ago in the yeast system
Saccharomyces cerevisiae by Herskowitz (Nature 329:219-222, 1987). It
20 has been demonstrated that over-expression of wild type gene products can result in a similar, dominant-negative inhibitory phenotype due most likely to the "saturating-out" of a factor, such as a protein, that is present at low levels and necessary for activity; removal of the protein by binding to a high level of its cognate partner results in the same net effect, leading to
25 inactivation of the protein and the associated signal transduction pathway.

Recently, work done by Nicolaides et.al. (32) has demonstrated the utility of introducing dominant negative inhibitory mismatch repair mutants into mammalian cells to confer global DNA hypermutability. There is a need in the art for additional techniques for generating mutations in
5 bacteria which can be used to make strains for production, biocatalysis, bioremediation, and drug discovery.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a method for
10 rendering bacterial cells hypermutable.

It is another object of the present invention to provide genetically altered bacteria.

It is yet another object of the present invention to provide a method to produce bacteria that are hypermutable.

15 It is an object of the invention to provide a method to inactivate the process that results in hypermutable cells following strain selection.

It is a further object of the invention to provide a method of mutating a gene of interest in a bacterium.

These and other embodiments of the invention are provided by one
20 or more of the embodiments described below. In one embodiment, a method is provided for making a hypermutable bacteria. A polynucleotide comprising a dominant negative allele of a mismatch repair gene is introduced into a bacterium, whereby the cell becomes hypermutable. Preferably the allele is under the control of an inducible transcription
25 regulatory sequence.

According to another aspect of the invention a homogeneous composition of cultured, hypermutable, bacteria is provided. The bacteria comprise a dominant negative allele of a mismatch repair gene. Preferably the allele is under the control of an inducible transcription regulatory
30 sequence.

Another embodiment of the invention provides a method for generating a mutation in a gene of interest. A bacterial culture comprising the gene of interest and a dominant negative allele of a mismatch repair gene is grown. The cell is hypermutable. It is tested to determine whether
5 the gene of interest harbors a mutation. Preferably the allele is under the control of an inducible transcription regulatory sequence.

According to still another aspect of the invention a method for generating a mutation in a gene of interest is provided. A bacterium comprising the gene of interest and a dominant negative allele of a
10 mismatch repair gene is grown to form a population of mutated bacteria. The population of mutated bacteria is cultivated under trait selection conditions. At least one of the cultivated bacteria is tested to determine that the gene of interest harbors a mutation. Preferably the allele is under the control of an inducible transcription regulatory sequence.

15 Still another aspect of the invention is a method for enhancing the mutation rate of a bacterium. A bacterium comprising a dominant negative allele of an MMR gene is exposed to a mutagen whereby the mutation rate of the bacterium is enhanced in excess of the rate in the absence of mutagen and in excess of the rate in the absence of the dominant negative allele.
20 Preferably the allele is under the control of an inducible transcription regulatory sequence.

Yet another aspect of the invention is a method for generating an MMR-proficient bacterium with a new output trait. A mismatch repair deficient bacterium comprising a gene of interest and a
25 dominant negative allele of a mismatch repair gene is grown to form a population of mutated bacteria. The population of mutated bacteria is cultivated under trait selection conditions. At least one of the cultivated bacteria is tested to determine that the gene of interest harbors a mutation. Mismatch repair activity is restored to the at least one of the cultivated

bacteria. Preferably the allele is under the control of an inducible transcription regulatory sequence.

- These and other embodiments of the invention provide the art with methods that can generate enhanced mutability in bacteria as well as
- 5 providing prokaryotic organisms harboring potentially useful mutations to generate novel output traits for commercial applications. The ability to create hypermutable organisms using dominant negative alleles has great commercial value for the generation of innovative bacterial strains that display new output features useful for a variety of applications, including
- 10 but not limited to the manufacturing industry for the generation of new biochemicals useful for detoxifying noxious chemicals from by-products of manufacturing processes or those used as catalysts, as well as helping in remediation of toxins present in the environment, including but not limited to polychlorobenzenes (PCBs), heavy metals and other environmental
- 15 hazards for which there is a need to remove them from the environment. In addition to obtaining organisms that are useful for removal of toxins from the environment, novel microbes can be selected for enhanced activity to either produce increased quantity or quality of a protein or non-protein therapeutic molecule by means of biotransformation (3).
- 20 Biotransformation is the enzymatic conversion, by a microbe or an extract derived from the microbe, of one chemical intermediate to the next product. There are many examples of biotransformation in use for the commercial manufacturing of important biological and chemical products, including Penicillin G, Erythromycin, and Clavulanic Acid as well as organisms that
- 25 are efficient at conversion of "raw" materials to advanced intermediates and/or final products (Berry, A. Trends Biotechnol. 14(7):250-256). The ability to control DNA hypermutability in host bacterial strains using a dominant negative MMR (as described above) allows for the generation of variant subtypes that can be selected for new phenotypes of commercial
- 30 interest, including but not limited to organisms that are toxin-resistant, have

the capacity to degrade a toxin *in situ* or the ability to convert a molecule from an intermediate to either an advanced intermediate or a final product. Other applications using dominant negative MMR genes to produce genetic alteration of bacterial hosts for new output traits include but are not limited to recombinant production strains that produce higher quantities of a recombinant polypeptide as well as the use of altered endogenous genes that can transform chemical or catalyze manufacturing downstream processes.

This application teaches of the use of a regulatable dominant negative MMR phenotype to produce a prokaryotic strain with a commercially beneficial output trait. Using this process, microbes expressing a dominant negative MMR can be directly selected for the phenotype of interest. Once a selected bacterium with a specified output trait is isolated, the hypermutable activity of the dominant negative MMR allele can be turned-off by several methods well known to those skilled in the art. For example, if the dominant-negative allele is expressed by an inducible promoter system, including but not limited to promoters such as: TAC-LACI, tryp (Brosius et.al. *Gene* 27:161-172, 1984), araBAD (Guzman et.al., *J. Bact.* 177:4121-4130, 1995) pLex (La Vallie et.al., *Bio.Technology* 11:187-193, 1992), pRSET (Schoepfer, R. *Gene* 124:83-85, 1993) , pT7 (Studier *J. Mol. Biol.* 219(1):37-44, 1991) etc., the inducer is removed and the promoter activity is reduced, or a system that excises the MMR gene insert from the host cells harboring the expression vector such as the Cre-lox (Hasan, N. et.al. *Gene* 2:51-56, 1994), as well as methods that can homologously knockout of the expression vector. In addition to the recombinant methods outlined above that have the capacity to eliminate the MMR activity from the microbe, it has been demonstrated that many chemicals have the ability to "cure" microbial cells of plasmids. For example, chemical treatment of cells with drugs including bleomycin (Attfield et al. *Antimicrob. Agents Chemother.* 27:985-988, 1985) or

novobiocin, coumermycin, and quinolones (Fu et al. *Chemotherapy* 34:415-418, 1988) have been shown to result in microbial cells that lack endogenous plasmid as evidenced by Southern analysis of cured cells as well as sensitivity to the appropriate antibiotic (1, 41-43). Whether by use
5 of recombinant means or treatment of cells with chemicals, removal of the MMR-expression plasmid results in the re-establishment of a genetically stable microbial cell-line. Therefore, the restoration of MMR allows host bacteria to function normally to repair DNA. The newly generated mutant bacterial strain that exhibits a novel, selected output trait is now suitable for
10 a wide range of commercial processes or for gene/protein discovery to identify new biomolecules that are involved in generating a particular output trait.

While it has been documented that MMR deficiency can lead to as much as a 1000-fold increase in the endogenous DNA mutation rate of a
15 host, there is no assurance that MMR deficiency alone will be sufficient to alter every gene within the DNA of the host bacterium to create altered biochemicals with new activity(s). Therefore, the use of chemical agents and their respective analogues such as ethidium bromide, EMS, MNNG, MNU, Tamoxifen, 8-Hydroxyguanine, as well as others listed but not
20 limited to in publications by: Khromov-Borisov, N.N., et.al. (*Mutat. Res.* 430:55-74, 1999); Ohe, T., et.al. (*Mutat. Res.* 429:189-199, 1999); Hour, T.C. et.al. (*Food Chem. Toxicol.* 37:569-579, 1999); Hrelia, P., et.al. (*Chem. Biol. Interact.* 118:99-111, 1999); Garganta, F., et.al. (*Environ. Mol. Mutagen.* 33:75-85, 1999); Ukawa-Ishikawa S., et.al. (*Mutat. Res.*
25 412:99-107, 1998); www.ehs.utah.edu/ohh/mutagens, etc. can be used to further enhance the spectrum of mutations and increase the likelihood of obtaining alterations in one or more genes that can in turn generate host bacteria with a desired new output trait(s) (10, 39, 40). Prior art teaches that mismatch repair deficiency leads to hosts with an increased resistance
30 to toxicity by chemicals with DNA damaging activity. This feature allows

for the creation of additional genetically diverse hosts when mismatch defective bacteria are exposed to such agents, which would be otherwise impossible due to the toxic effects of such chemical mutagens [Colella, G., et.al. (Br. J. Cancer 80:338-343, 1999); Moreland, N.J., et.al. (Cancer Res. 59:2102-2106, 1999); Humbert, O., et.al. (Carcinogenesis 20:205-214, 1999); Glaab, W.E., et.al. (Mutat. Res. 398:197-207, 1998)]. Moreover, prior art teaches that mismatch repair is responsible for repairing chemical-induced DNA adducts, so therefore blocking this process could theoretically increase the number, types, mutation rate and genomic alterations of a bacterial host [Rasmussen, L.J. et.al. (Carcinogenesis 17:2085-2088, 1996); Sledziowska-Gojska, E., et.al. (Mutat. Res. 383:31-37, 1997); and Janion, C. et.al. (Mutat. Res. 210:15-22, 1989)]. In addition to the chemicals listed above, other types of DNA mutagens include ionizing radiation and UV-irradiation, which are known to cause DNA mutagenesis in bacteria can also be used to potentially enhance this process. These agents which are extremely toxic to host cells and therefore result in a decrease in the actual pool size of altered bacterial cells are more tolerated in MMR defective hosts and in turn allow for a enriched spectrum and degree of genomic mutation (7).

20 This application teaches new uses of MMR deficient bacterial cells to create commercially viable microbes that express novel output traits. Moreover, this application teaches the use of dominant negative MMR genes to decrease the endogenous MMR activity of the host followed by placing the cells under selection to obtain a desired, sought after output trait for commercial applications such as but not limited to recombinant manufacturing, biotransformation and bioremediation. Furthermore, the application teaches the use of restoring MMR activity to the hypermutable bacterial host following strain selection of the variant of interest as a means to genetically "fix" the new mutations in the host genome. The application also teaches the use of enhanced hypermutability in bacteria by using

MMR deficiency and chemical or radiation mutagenesis to create variant subtypes of bacteria useful for commercial and other applications. The application describes uses of hypermutable bacteria for producing strains that can be used to generate new output traits for chemical manufacturing, pharmaceutical and other commercially applicable processes.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Western blot of steady-state PMS134 levels in IPTG-treated samples in DH10B strain. Cells containing the pTACPMS134 (lane 2) showed a robust steady state level of protein after induction in contrast to cells expressing empty vector (lane 1). Blots were probed with an anti-human-PMS2 polyclonal antibody.

Figure 2. Western blot of PMS134V5 and PMSR3V5 in IPTG-treated (+) and untreated (-) samples in BL21 strain. Blots were probed with an anti-V5 antibody, which is directed to the C-terminal tag of each protein.

Figure 3. Number of Kanamycin resistant PMS134 and vector control DH10B clones. IPTG-induced strains were grown and plated onto KAN plates and grown for 18 hours at 37°C to identify number of KAN resistant clones due to genetic alteration.

Figure 4. Number of Kanamycin Resistant PMS134, PMSR3 and vector control BL21 clones. IPTG-induced strains were grown and plated onto AMP and KAN plates and grown for 18 hours at 37°C to identify number of KAN resistant clones due to genetic alteration.

Figure 5. (A) Western blot of steady-state ATPMS134flag in IPTG-treated samples in DH10B. Lysates from untransfected cells (lane 1) and a

bacterial clone expressing the *Arabidopsis thaliana* PMS134 truncated protein with a FLAG epitope fused to the C-terminus (ATPMS134flag) (lane 2) were electrophoresed on SDS-PAGE gels. Blots were probed with an anti-FLAG monoclonal antibody directed to the FLAG epitope. (B)

- 5 Number of Kanamycin Resistant ATPMS134flag and vector control DH10B clones. IPTG-induced strains were grown and plated onto AMP and KAN plates and grown for an additional 18 hours at 37°C to identify number of KAN resistant clones due to genetic alteration.

- 10 **Figure 6.** Generation of high recombinant producer BGAL-MOR lines in PMS134 expressing DH5alpha host strains.

DETAILED DESCRIPTION OF THE INVENTION

- 15 The inventors present a method for developing hypermutable bacteria by altering the activity of endogenous mismatch repair activity of hosts. Wild type and some dominant negative alleles of mismatch repair genes, when introduced and expressed in bacteria, increase the rate of spontaneous mutations by reducing the effectiveness of the endogenous
- 20 MMR-mediated DNA repair activity, thereby rendering the bacteria highly susceptible to genetic alterations due to hypermutability. Hypermutable bacteria can then be utilized to screen for novel mutations in a gene or a set of genes that produce variant siblings that exhibit a new output trait(s) not found in the wild type cells.

- 25 The process of mismatch repair, also called mismatch proofreading, is an evolutionarily highly conserved process that is carried out by protein complexes described in cells as disparate as prokaryotic cells such as bacteria to more complex mammalian cells (14, 29, 31, 33, 34). A mismatch repair gene is a gene that encodes one of the proteins of such a
- 30 mismatch repair complex. Although not wanting to be bound by any

particular theory of mechanism of action, a mismatch repair complex is believed to detect distortions of the DNA helix resulting from non-complementary pairing of nucleotide bases. The non-complementary base on the newer DNA strand is excised, and the excised base is replaced with
5 the appropriate base that is complementary to the older DNA strand. In this way, cells eliminate many mutations that occur as a result of mistakes in DNA replication, resulting in genetic stability of the sibling cells derived from the parental cell.

Some wild type alleles as well as dominant negative alleles cause a
10 mismatch repair defective phenotype even in the presence of a wild-type allele in the same cell. An example of a dominant negative allele of a mismatch repair gene is the human gene *hPMS2-134*, which carries a truncation mutation at codon 134 (32). The mutation causes the product of this gene to abnormally terminate at the position of the 134th amino acid,
15 resulting in a shortened polypeptide containing the N-terminal 133 amino acids. Such a mutation causes an increase in the rate of mutations, which accumulate in cells after DNA replication. Expression of a dominant negative allele of a mismatch repair gene results in impairment of mismatch repair activity, even in the presence of the wild-type allele. Any
20 mismatch repair allele, which produces such effect, can be used in this invention. In addition, the use of over-expressed wildtype MMR gene alleles from human, mouse, plants, and yeast in bacteria has been shown to cause a dominant negative effect on the bacterial hosts MMR activity (9, 33, 34, 38).

25 Dominant negative alleles of a mismatch repair gene can be obtained from the cells of humans, animals, yeast, bacteria, plants or other organisms. Screening cells for defective mismatch repair activity can identify such alleles. Mismatch repair genes may be mutant or wild type. Bacterial host MMR may be mutated or not. The term bacteria used in this
30 application include any organism from the prokaryotic *kingdom*. These

- organisms include genera such as but not limited to *Agrobacterium*,
Anaerobacter, *Aquabacterium*, *Azorhizobium*, *Bacillus*, *Bradyrhizobium*,
Cryobacterium, *Escherichia*, *Enterococcus*, *Heliobacterium*, *Klebsiella*,
Lactobacillus, *Methanococcus*, *Methanothermobacter*, *Micrococcus*,
5 *Mycobacterium*, *Oceanomonas*, *Pseudomonas*, *Rhizobium*,
Staphylococcus, *Streptococcus*, *Streptomyces*, *Thermusaquaticus*,
Thermaerobacter, *Thermobacillus*, etc. Other procaryotes that can be used
for this application are listed at (www.bacterio.cict.fr/validgenericnames).
Bacteria exposed to chemical mutagens or radiation exposure can be
10 screened for defective mismatch repair. Genomic DNA, cDNA, or mRNA
from any cell encoding a mismatch repair protein can be analyzed for
variations from the wild type sequence. Dominant negative alleles of a
mismatch repair gene can also be created artificially, for example, by
producing variants of the *hPMS2-134* allele or other mismatch repair genes
15 (32). Various techniques of site-directed mutagenesis can be used. The
suitability of such alleles, whether natural or artificial, for use in generating
hypermutable bacteria can be evaluated by testing the mismatch repair
activity (using methods described in ref 32) caused by the allele in the
presence of one or more wild-type alleles, to determine if it is a dominant
20 negative allele.

- A bacterium that over-expresses a wild type mismatch repair allele
or a dominant negative allele of a mismatch repair gene will become
hypermutable. This means that the spontaneous mutation rate of such
bacteria is elevated compared to bacteria without such alleles. The degree
25 of elevation of the spontaneous mutation rate can be at least 2-fold, 5-fold,
10-fold, 20-fold, 50-fold, 100-fold, 200-fold, 500-fold, or 1000-fold that of
the normal bacteria as measured as a function of bacterial doubling/minute.

- According to one aspect of the invention, a polynucleotide encoding
either a wild type or a dominant negative form of a mismatch repair protein
30 is introduced into bacteria. The gene can be any dominant negative allele

encoding a protein which is part of a mismatch repair complex, for example, *mutS*, *mutL*, *mutH*, or *mutY* homologs of the bacterial, yeast, plant or mammalian genes (14, 28). The dominant negative allele can be naturally occurring or made in the laboratory. The polynucleotide can be in
5 the form of genomic DNA, cDNA, RNA, or a chemically synthesized polynucleotide or polypeptide. The molecule can be introduced into the cell by transfection, transformation, conjugation, fusion, or other methods well described in the literature.

Any process can be used whereby a polynucleotide or polypeptide
10 is introduced into a cell. The process of gene transfer can be carried out in a bacterial culture using a suspension culture. The bacteria can be any type classified under the prokaryotes.

In general, gene transfer will be carried out using a suspension of cells but other methods can also be employed as long as a sufficient
15 fraction of the treated cells incorporate the polynucleotide or polypeptide so as to allow recipient cells to be grown and utilized. The protein product of the polynucleotide may be transiently or stably expressed in the cell. Techniques for gene transfer are well known to those skilled in the art. Available techniques to introduce a polynucleotide or polypeptide into a
20 prokaryote include but are not limited to electroporation, transduction, cell fusion, the use of chemically competent cells (e.g. calcium chloride), and packaging of the polynucleotide together with lipid for fusion with the cells of interest. Once a cell has been transformed with the dominant negative mismatch repair gene or protein, the cell can be propagated and
25 manipulated in either liquid culture or on a solid agar matrix, such as a petri dish. If the transfected cell is stable, the gene will be retained and expressed at a consistent level when the promoter is constitutively active, or when in the presence of appropriate inducer molecules when the promoter is inducible, for many cell generations, and a stable,
30 hypermutable bacterial strain results.

An isolated bacterial cell is a clone obtained from a pool of a bacterial culture by chemically selecting out non-recipient strains using, for example, antibiotic selection of an expression vector. If the bacterial cell is derived from a single cell, it is defined as a clone.

- 5 A polynucleotide encoding a dominant negative form of a mismatch repair protein can be introduced into the genome of a bacterium or propagated on an extra-chromosomal plasmid. Selection of clones harboring the mismatch repair gene expression vector can be accomplished by addition of any of several different antibiotics, including but not limited to ampicillin, kanamycin, chloramphenicol, zeocin, and tetracycline. The
- 10 microbe can be any species for which suitable techniques are available to produce transgenic microorganisms, such as but not limited to genera including *Bacillus*, *Pseudomonas*, *Staphylococcus*, *Escherichia* and others.

- Any method for making transgenic bacteria known in the art can be
- 15 used. According to one process of producing a transgenic microorganism, the polynucleotide is transfected into the microbe by one of the methods well known to those in the art. Next, the microbial culture is grown under conditions that select for cells in which the polynucleotide encoding the mismatch repair gene is either incorporated into the host genome as a stable
- 20 entity or propagated on a self-replicating extra-chromosomal plasmid, and the protein encoded by the polynucleotide fragment transcribed and subsequently translated into a functional protein within the cell. Once transgenic microbe is engineered to harbor the expression construct, it is then propagated to generate and sustain a culture of transgenic microbes
- 25 indefinitely.

- Once a stable, transgenic microorganism has been engineered to express a functional mismatch repair (MMR) protein, the microbe can be exploited to create novel mutations in one or more target gene(s) of interest harbored within the same microorganism. A gene of interest can be any
- 30 gene naturally possessed by the bacterium or one introduced into the

bacterial host by standard recombinant DNA techniques. The target gene(s) may be known prior to the selection or unknown. One advantage of employing such transgenic microbes to induce mutations in resident or extra-chromosomal genes within the microbe is that it is unnecessary to expose the microorganism to mutagenic insult, whether it be chemical or radiation in nature, to produce a series of random gene alterations in the target gene(s). This is due to the highly efficient nature and the spectrum of naturally occurring mutations that result as a consequence of the altered mismatch repair process. However, it is possible to increase the spectrum and frequency of mutations by the concomitant use of either chemicals and/or radiation together with MMR defective cells. These include DNA mutagens, DNA alkylating agents, DNA intercalating agents, DNA oxidizing agents, ionizing radiation, and ultraviolet radiation. The net effect of the combination treatment is the increase in altered gene pool in the genetically altered microbe that result in an increased alteration of an allele(s) that are useful for producing new output traits. Another benefit of using MMR-defective microbes that are taught in this application is that one can perform a genetic screen for the direct selection of variant sub-clones that exhibit new output traits with commercially important applications. This allows one to bypass tedious and time consuming gene identification, isolation and characterization.

Mutations can be detected by analyzing the recombinant microbe for alterations in the genotype and/or phenotype post-activation of the decreased mismatch repair activity of the transgenic microorganism. Novel genes that produce altered phenotypes in MMR-defective microbial cells can be discerned by any variety of molecular techniques well known to those in the art. For example, the microbial genome can be isolated and a library of restriction fragments cloned into a plasmid vector. The library can be introduced into a "normal" cell and the cells exhibiting the novel phenotype screened. A plasmid is isolated from those normal cells that

exhibit the novel phenotype and the gene(s) characterized by DNA sequence analysis. Alternatively, differential messenger RNA screen can be employed utilizing driver and tester RNA (derived from wild type and novel mutant respectively) followed by cloning the differential transcripts and characterizing them by standard molecular biology methods well known to those skilled in the art. Furthermore, if the mutant sought is on encoded by an extrachromosomal plasmid, then following co-expression of the dominant negative MMR gene and the gene of interest to be altered and phenotypic selection, the plasmid is isolated from mutant clones and analyzed by DNA sequence analysis by methods well known to those in the art. Phenotypic screening for output traits in MMR-defective mutants can be by biochemical activity and/or a physical phenotype of the altered gene product. A mutant phenotype can also be detected by identifying alterations in electrophoretic mobility, DNA binding in the case of transcription factors, spectroscopic properties such as IR, CD, X-ray crystallography or high field NMR analysis, or other physical or structural characteristics of a protein encoded by a mutant gene. It is also possible to screen for altered novel function of a protein *in situ*, in isolated form, or in model systems. One can screen for alteration of any property of the microorganism associated with the function of the gene of interest, whether the gene is known prior to the selection or unknown. The aforementioned screening and selection discussion is meant to illustrate the potential means of obtaining novel mutants with commercially valuable output traits.

Plasmid expression vectors that harbor the mismatch repair (MMR) gene inserts can be used in combination with a number of commercially available regulatory sequences to control both the temporal and quantitative biochemical expression level of the dominant negative MMR protein. The regulatory sequences can be comprised of a promoter, enhancer or promoter/enhancer combination and can be inserted either upstream or downstream of the MMR gene to control the expression level. The

regulatory promoter sequence can be any of those well known to those in the art, including but not limited to the lacI, tetracycline, tryptophan-inducible, phosphate inducible, T7-polymerase-inducible (30), and steroid inducible constructs as well as sequences which can result in the excision
5 of the dominant negative mismatch repair gene such as those of the Cre-Lox system. These types of regulatory systems are familiar to those skilled in the art.

Once a microorganism with a novel, desired output trait of interest is created, the activity of the aberrant MMR activity can be attenuated or
10 eliminated by any of a variety of methods, including removal of the inducer from the culture medium that is responsible for promoter activation, gene disruption of the aberrant MMR gene constructs, electroporation and/or chemical curing of the expression plasmids (Brosius, Biotechnology 10:205-225, 1988; Wang et al., J. of Fujian Agricultural University 28:43-
15 46, 1999; Fu et. al., Chem Abstracts 34:415-418, 1988). The resulting microbe is now useful as a stable strain that can be applied to various commercial applications, depending upon the selection process placed upon it.

In cases where genetically deficient mismatch repair bacteria
20 [strains such as but not limited to: M1 (mutS) and in EC2416 (mutS delta umuDC), and mutL or mutY strains] are used to derive new output traits, transgenic constructs can be used that express wild-type mismatch repair genes sufficient to complement the genetic defect and therefore restore mismatch repair activity of the host after trait selection [Grzesiuk, E. et.al.
25 (Mutagenesis 13:127-132, 1998); Bridges, B.A., et.al. (EMBO J. 16:3349-3356, 1997); LeClerc, J.E., Science 15:1208-1211, 1996); Jaworski, A. et.al. (Proc. Natl. Acad. Sci USA 92:11019-11023, 1995)]. The resulting microbe is genetically stable and can be applied to various commercial practices.

The use of over expressing foreign mismatch repair genes from human and yeast such as PMS1, MSH2, MLH1, MLH3, etc. have been previously demonstrated to produce a dominant negative mutator phenotype in bacterial hosts (35, 36, 37). In addition, the use of bacterial strains expressing prokaryotic dominant negative MMR genes as well as hosts that have genomic defects in endogenous MMR proteins have also been previously shown to result in a dominant negative mutator phenotype (29,32). However, the findings disclosed here teach the use of MMR genes, including the human PMSR2 and PMSR3 gene (ref 19), the related PMS134 truncated MMR gene (ref 32), the plant mismatch repair genes (SARAH include Plant patent application) and those genes that are homologous to the 134 N-terminal amino acids of the PMS2 gene which include the MutL family of MMR proteins and including the PMSR and PMS2L homologs described by Hori et.al. (accession number NM_005394 and NM_005395) and Nicolaides (reference 19) to create hypermutable microbes. In addition, this application teaches the use of DNA mutagens in combination with MMR defective microbial hosts to enhance the hypermutable production of genetic alterations. This accentuates MMR activity for generation of microorganisms with commercially relevant output traits such as but not limited to recombinant protein production strains, biotransformation, and bioremediation.

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples that will be provided herein for purposes of illustration only, and are not intended to limit the scope of the invention

EXAMPLES

Example 1: Generation of inducible MMR dominant negative allele vectors

Bacterial expression constructs were prepared to determine if the human PMS2 related gene (hPMSR3) (19) and the human PMS134 gene (32) are capable of inactivating the bacterial MMR activity and thereby increase the overall frequency of genomic hypermutation, a consequence of which is the generation of variant sib cells with novel output traits following host selection. Moreover, the use of regulatable expression vectors will allow for suppression of dominant negative MMR alleles and restoration of the MMR pathway and genetic stability in hosts cells (43). For these studies, a plasmid encoding the hPMS134 cDNA was altered by polymerase chain reaction (PCR). The 5' oligonucleotide has the following structure: 5'-ACG CAT ATG GAG CGA GCT GAG AGC TCG AGT-3' that includes the NdeI restriction site CAT ATG. The 3'-oligonucleotide has the following structure: 5'-GAA TTC TTA TCA CGT AGA ATC GAG ACC GAG GAG AGG GTT AGG GAT AGG CTT ACC AGT TCC AAC CTT CGC CGA TGC-3' that includes an EcoRI site GAA TTC and the 14 amino acid epitope for the V5 antibody. The oligonucleotides were used for PCR under standard conditions that included 25 cycles of PCR (95°C for 1 minute, 55°C for 1 minute, 72°C for 1.5 minutes for 25 cycles followed by 3 minutes at 72°C). The PCR fragment was purified by gel electrophoresis and cloned into pTA2.1 (InVitrogen) by standard cloning methods (Sambrook et al., Molecular Cloning: A Laboratory Manual, Third Edition, 2001), creating the plasmid pTA2.1-hPMS134. pTA2.1-hPMS134 was digested with the restriction enzyme EcoRI to release the insert (there are two EcoRI restriction sites in the multiple cloning site of pTA2.1 that flank the insert) and the fragment filled in with Klenow fragment and dNTPs. Next, the fragment was gel purified, then digested with NdeI and inserted in pT7-Ea that had been digested with NdeI and BamHI (filled

with Klenow) and phosphatase treated. The new plasmid was designated pT7-Ea-hPMS134. The following strategy, similar to that described above to clone human PMS134, was used to construct an expression vector for the human related gene PMSR3. First, the hPMSR3 fragment was amplified
5 by PCR to introduce two restriction sites, an NdeI restriction site at the 5'-end and an EcoRI site at the 3'-end of the fragment. The 5'-oligonucleotide that was used for PCR has the following structure: 5'-ACG CAT ATG TGT CCT TGG CGG CCT AGA-3' that includes the NdeI restriction site CAT ATG. The 3'-oligonucleotide used for PCR has the
10 following structure: 5'-GAA TTC TTA TTA CGT AGA ATC GAG ACC GAG GAG AGG GTT AGG GAT AGG CTT ACC CAT GTG TGA TGT TTC AGA GCT-3' that includes an EcoRI site GAA TTC and the V5 epitope to allow for antibody detection. The plasmid that contained human PMSR3 in pBluescript SK (19) was used as the PCR target with the
15 hPMS2-specific oligonucleotides above. Following 25 cycles of PCR (95°C for 1 minute, 55°C for 1 minute, 72°C for 1.5 minutes for 25 cycles followed by 3 minutes at 72°C). The PCR fragment was purified by gel electrophoresis and cloned into pTA2.1 (InVitrogen) by standard cloning methods (Sambrook et al., Molecular Cloning: A Laboratory Manual, Third
20 Edition, 2001), creating the plasmid pTA2.1-hR3. pTA2.1-hR3 was next digested with the restriction enzyme EcoRI to release the insert (there are two EcoRI restriction sites in the multiple cloning site of pTA2.1 that flank the insert) and the fragment filled in with Klenow fragment and dNTPs. Then, the fragment was gel purified, then digested with NdeI and inserted
25 in pT7-Ea that had been digested with NdeI and BamHI (filled with Klenow) and phosphatase treated. The new plasmid was designated pT7-Ea-hR3.

BL21 cells harbor an additional expression vector for the lysozyme protein, which has been demonstrated to bind to the T7 polymerase in situ;
30 this results in a bacterial strain that has very low levels of T7 polymerase

expression. However, upon addition of the inducer IPTG, the cells express high-levels of T7 polymerase due to the IPTG-inducible element that drives expression of the polymerase that is resident within the genome of the BL21 cells (30). The BL21 cells are chloramphenicol resistant due to the plasmid that expresses lysozyme within the cell. To introduce the pT7-hPMS134 or the pT7-hPMSR3 genes into BL21 cells, the cells were made competent by incubating the cells in ice cold 50mM CaCl₂ for 20 minutes, followed by concentrating the cells and adding super-coiled plasmid DNA as describe (Maniatis, T.et.al. Cold Spring Harbor Laboratory Press, Third Edition, 2001). Ampicillin resistant BL21 were selected on LB-agar plates [5% yeast extract, 10% bactotryptone, 5% NaCl, 1.5% bactoagar , pH 7.0 (Difco)] plates containing 25 µg/ml chloramphenicol and 100µg/ml ampicillin. The next day, bacterial colonies were picked and analyzed for vectors containing an intact pTACPMS134 or pTAC empty vector by restriction endonuclease digestion and sequence analysis.

In addition to constructing a V5-epitope tagged PMS134 construct we also constructed and tested a non-epitope tagged version. This was prepared to demonstrate that the simple fact of epitope tagging the construct did not result in alteration of the dominant-negative phenotype that PMS134 has on mismatch repair activity. For these studies, a BamHI restriction fragment containing the hPMS134 cDNA was filled-in with Klenow fragment and then sub-cloned into a Klenow-filled blunt-ended NdeI-XhoI site of the pTACLAC expression vector, which contains the isopropylthio-β-galactosidase (IPTG)-inducible bacterial TAC promoter and ampicillin resistance gene as selectable marker. The NdeI-XhoI cloning site is flanked by the TACLAC promoter that contains the LacI repressor site followed by a Shine Dalgarno ribosome-binding site at the 5' flanking region and the T1T2 ribosomal RNA terminator in the 3' flanking region. The TACLAC vector also contains the LacI gene, which is constitutively expressed by the TAC promoter.

DH10B bacterial cells containing the pBCSK vector (Stratagene), which constitutively expresses the β -galactosidase gene and contains the chloramphenicol resistance marker for selection, were made competent via the CaCl_2 method (Maniatis, T. et al. Cold Spring Harbor Laboratory Press, 1982). This vector turns bacterial cells blue when grown in the presence of IPTG and X-gal that aids in the detection of bacterial colonies. Competent cells were transfected with the pTAC empty vector or the pTACPMS134 vector following the heat-shock protocol. Transfected cultures were plated onto LB-agar [5% yeast extract, 10% bacto-tryptone, 5% NaCl, 1.5% bacto-agar, pH 7.0 (Difco)] plates containing 25 $\mu\text{g/ml}$ chloramphenicol and 100 $\mu\text{g/ml}$ ampicillin. The next day, bacterial colonies were picked and analyzed for vectors containing an intact pTACPMS134 or pTAC empty vector by restriction endonuclease digestion and sequence analysis. Ten clones of each bacteria containing correct empty or PMS134 inserts were then grown to confluence overnight in LB media (5% yeast extract, 10% bacto-tryptone, 5% NaCl, pH 7.0) containing 10 $\mu\text{g/ml}$ chloramphenicol and 50 $\mu\text{g/ml}$ ampicillin. The next day TAC empty or pTACPMS134 cultures were diluted 1:4 in LB medium plus 50 μM IPTG (Gold Biotechnology) and cultures were grown for 12 and 24 hours at 37°C. After incubation, 50 μl aliquots were taken from each culture and added to 150 μl of 2X SDS buffer and cultures were analyzed for PMS134 protein expression by western blot.

Western blots were carried out as follows. 50 μl of each PMS134 or empty vector culture was directly lysed in 2X lysis buffer (60 mM Tris, pH 6.8, 2% SDS, 10% glycerol, 0.1 M 2-mercaptoethanol, 0.001% bromophenol blue) and samples were boiled for 5 minutes. Lysate proteins were separated by electrophoresis on 4-20% Tris glycine gels (Novex). Gels were electroblotted onto Immobilon-P (Millipore) in 48 mM Tris base, 40 mM glycine, 0.0375% SDS, 20% methanol and blocked overnight

at 4°C in Tris-buffered saline plus 0.05% Tween-20 and 5% condensed milk. Filters were probed with a rabbit polyclonal antibody generated against the N-terminus of the human PMS2 polypeptide (Santa Cruz), which is able to recognize the PMS134 polypeptide (31), followed by a
5 secondary goat anti-rabbit horseradish peroxidase-conjugated antibody. After incubation with the secondary antibody, blots are developed using chemiluminescence (Pierce) and exposed to film to measure PMS134 expression.

As shown in Figure 1, a robust expression of PMS134 could be
10 detected in bacterial cells containing pTACPMS134 (lane 2) in contrast to cells expressing empty vector (lane 1), which had no signal.

For induction of PMS134 and PMSR3 in BL21 cells, the pT7-Ea-hPMS134 or the pT7-Ea-hPMSR3 cells were induced with 50µM IPTG for 12 and 24 hours. Cell lysates were prepared and analyzed by western blot
15 listed above using either the N-terminal PMS2 antibody to detect the PMS134 containing cells or the antiV5-horseradish peroxidase conjugated monoclonal antibody (InVitrogen) to detect the PMS134V5 and PMSR3V5 polypeptides. Figure 2 shows the expression of PMS134V5 and PMSR3V5 before (-) lanes and after IPTG (+) lanes induction.

20

Example 2: Generation of hypermutable bacteria with inducible dominant negative alleles of mismatch repair genes

Bacterial clones expressing the *PMS134* or the empty vector were
25 grown in liquid culture for 24 hr at 37°C in the presence of 10 µg/ml chloramphenicol and 50 µg/ml ampicillin plus 50µM IPTG. The next day, cultures were diluted 1:10 in medium containing 50µM IPTG plus ampicillin/chloramphenicol (AC) or ampicillin/chloramphenicol plus 25 µg/ml kanamycin (ACK) and cultures were grown for 18 hr at 37°C. The
30 following day, a 0.1 µl aliquot (2 µl diluted in 1000 µl of LB medium and

used 50 µl for plating) of cells grown in AC medium were plated on LB-agar plates containing 40 µg/ml of 5-bromo-4-chloro-3-indolyl-B-D-galactoside (X-gal) plus 100µg/ml ampicillin (AMP), while a 1 µl aliquot (1 µl diluted in 100 µl of LB medium and used 100 µl for plating) of cells
5 grown in ACK medium were plated on LB-agar plates containing X-gal and 50µg/ml kanamycin (KAN). Plates were incubated for 18 hours at 37°C. The results from these studies show that cells expressing the *PMS134* were able to increase hypermutation in the genome of the DH10B bacterial strain which resulted in the production of siblings that exhibit new
10 biological traits such as KAN resistance (Figure 3).

Kanamycin-resistant assays using BL21 cells expressing the V5-tagged or untagged PMS134 or PMSR3 polypeptides were carried out as described above. BL21 bacterial cells that harbor the empty vector, pT7-PMS134 or pT7-PMSR3 were grown overnight in
15 LB supplemented with 100ug/ml ampicillin. The overnight cultures were diluted 1:100 into fresh ampicillin containing medium and grown for 2.5 hours at 37°C with continuous shaking. When the cells reached an optical density (OD) of 0.6, measured at 600nm, IPTG was added to each culture to a final concentration of 0.5mM. Cells
20 were incubated for 24, and 48 hours; at those time points cells were removed for SDS-PAGE analysis and plating (see above). BL21/pT7 (empty vector), BL21/pT7-PMS134, and BL21/pT7-R3 cells were plated onto LB plates, LB plates that contained 100ug/ml ampicillin, and plates that contain 50ug/ml Kanamycin. The
25 equivalent of 1×10^7 cells/plate were spread onto the plates. BL21 cells that harbor the empty vector are capable of growth on LB plates as well as LB plates that contain 100ug/ml ampicillin; that is as expected since the pT7 expression vector renders the cells ampicillin resistant. The vector only control is not capable of growth on
30 Kanamycin. After 24hr IPTG-induction PMS134 or PMSR3 cells

had a significant number of KAN resistant cells while none were observed in BL21 parental cells grown under similar conditions (Figure 4). Moreover, BL21 cells containing the PMS134 or PMSR3 genes under non-IPTG-induced conditions failed to produce any

- 5 KAN resistant clones demonstrating the need for expression of the PMS polypeptides for hypermutability. A summary outlining the data

and number of Kanamycin resistant bacterial clones is provided in TABLE 1.

10

TABLE 1. Generation of Kanamycin resistant clones via MMR deficiency

STRAIN	# CELLS SEEDED	AMP ^R colonies	KAN ^R colonies	FREQUENCY
DH10B VEC	50,000	62,000	0	0
DH10B PMS134	50,000	43,146	23	5.3×10^{-4}
BL21 VEC	500,000	520,80 0	0	0
BL21 T7-Ea-PMS134V5	500,000	450,00 0	2,245	4.9×10^{-3}
BL21 T7-Ea-PMSR3V5	500,000	500,00 0	1,535	3.1×10^{-3}

These data demonstrate and enable the proof-of-concept that the use of the dominant negative MMR genes is a viable approach to creating hypermutable bacteria that can lead to the generation of phenotypically

- 15 diverse offspring when put under selective conditions.

Using the same protocol as listed above and the same cloning strategy, a truncated PMS2 homolog from the *Arabidopsis thaliana* plant (reference the PLANT patent), which was cloned by degenerate PCR from an *Arabidopsis thaliana* cDNA library

(Stratagene), was found to give a similar enhancement of genetic hypermutability in DH5alpha bacteria Figure 5. For detection purposes, we fused a FLAG epitope to the C-terminus of the PMS134 polypeptide using PCR and an antisense primer directed to the 134 codon region of the *Arabidopsis* PMS2 homolog followed by a FLAG epitope and 2 termination codons. The resultant fusion was termed ATPMS134-flag. The AT PMS134-flag gene was then cloned into the IPTG-inducible TACLAC expression vector and transfected into DH5alpha cells. Western blot of bacteria transfected with an IPTG-inducible expression vector carrying a truncated version (codons 1-134) of the *Arabidopsis thaliana* PMS2 homolog using the anti-FLAG antibody demonstrated the inducibility and steady-state protein levels of the chimeric gene. Figure 5A shows the western blot containing protein from an untransfected cell (lane 1) and a bacterial clone expressing the *Arabidopsis* PMS2-134 truncated protein (lane 2). Following the mutagenesis protocol described above, bacterial cells expressing the ATPMS134 protein were found to have an increase in the number of KAN resistant cells (12 clones) in contrast to cells expressing the empty vector that yielded no KAN resistant clone.

Bacterial cells such as the pT7-PMS134 and pT7-R3 harboring BL21 cells; the TACLACPMS134 DH10B; the TACLACMLH1 DH10B cells; or the TACLAC-ATPMS134flag DH5alpha cells are capable of growth on LB, LB/ampicillin and LB/KAN plates because the cells have acquired mutations within their genome that render the cell drug resistant. Cells that express dominant negative MMR genes have altered the mismatch control pathway of the microbe, presumably altering a gene or a set of genes that control resistance to kanamycin. A new output trait, Kanamycin-resistance, is generated by expression of the dominant negative MMR

gene in these cells. These data demonstrate the ability of dominant negative MMR genes to produce hypermutability across a wide array of bacterial strains to produce new output traits such as Kanamycin resistance.

5

EXAMPLE 3: Dominant negative MMR genes can produce new genetic variants and commercially viable output traits in prokaryotic organisms.

10 The data presented in EXAMPLE 2 show the ability to generate genetic alterations and new phenotypes in bacterial strains expressing dominant negative MMR genes. In this EXAMPLE we teach the utility of this method to create prokaryotic strains with commercially relevant output traits.

15

GENERATION OF HEAT-RESISTANT PRODUCER STRAINS.

One example of commercial utility is the generation of heat-resistant recombinant protein producer strains. In the scalable process of recombinant manufacturing, large-scale fermentation of prokaryotes results in the generation of heat, which leads to suboptimal growth conditions for the producer strain and thus resulting in lower recombinant protein yields. In order to circumvent this problem, we employed the use of DH10B bacteria containing the inducible TACLACPMS134 gene. Briefly, cells were grown in 5 ml LB shake flasks containing ampicillin and IPTG-induced for 0, 24 and 48hrs at 37C. Cultures were harvested and then incubated at 100C for 0, 1 or 10 minutes (times at which 100% of the wild-type strain perishes) and 100 µl aliquots (equivalent to 250,000 cells) were
25 plated onto LB agar plates containing ampicillin to identify heat
30

resistant clones. Table 2 shows a typical experiment whereby cells containing the TACLACPMS134 gene generated a significant number of heat-resistant clones after 48 hours of PMS134 induction and hypermutation via MMR blockade. No or a few clones were observed in the uninduced or 24hr induced conditions respectively suggesting the needs for multiple rounds of genetic mutation to produce genes that are capable of allowing bacteria to survive under harsh conditions. Similar results were observed with other dominant negative mutants such as the PMSR2, PMSR3, and the human MLH1 proteins (not shown).

TABLE 2. Generation of heat-resistant clones via MMR deficiency

Treatment	Heated 0 min	Heated 1 min	Heated 10 min
TACLACVEC 0 hr IPTG	250,000 +/- 7,500	0	0
TACLACPMS134 0 hr IPTG	265,000 +/- 2,000	0	0
TACLACVEC 24 hr IPTG	274,000 +/- 12,000	1 +/- 0	0
TACLACPMS134 24 hr IPTG	240,000 +/- 9,400	5 +/- 2	0
TACLACVEC 48 hr IPTG	256,000 +/- 12,000	0	0
TACLACPMS134 48 hr IPTG	252,000 +/- 14,000	65 +/- 8	3 +/- 1

15 GENERATION OF HIGH RECOMBINANT PROTEIN PRODUCER STRAINS.

Next, we tested the ability of bacteria expressing dominant negative MMR genes to produce subclones with enhanced recombinant protein production. In these experiments again we employed the DH10B cells containing the TACLACPMS134 inducible vector plus the pTLACZ vector, which constitutively

expresses the β -galactosidase gene. Analysis of individual clones containing the TACLACPMS134 and pTLACZ vector typically produces 10-20 μ g/ml of LACZ protein via shake flask fermentation after IPTG induction for 24 hours. To test the hypothesis that high recombinant producer strains can be generated by decreased MMR in bacterial strains, we induced the TACLACPMS134-pTLACZ cells for 48 hours with IPTG as described above. We then diluted the culture 1:50 in LB medium, grew the strain for 24 hours, and plated 10 μ ls of culture (diluted in 300 μ ls of LB) onto LB amp-XGAL plates to identify candidate clones that produce robust levels of recombinant LACZ protein. As a control, uninduced cells were treated similarly and plated onto LB amp-XGAL plates. Analysis of the plates revealed a number of bacterial colonies exhibiting a number of clones with an intense BLUE staining in the TACLACPMS134/pTLACZ cells induced with IPTG but none were observed in uninduced clones (Figure 6). To confirm that these clones produced an enhanced level of LACZ, we expanded 2 clones with an average BLUE stain (BGAL-C1 and BGAL-C2) and 10 clones with a robust BLUE staining (BGAL-MOR1 to BGAL-MOR10). We grew all clones in LB AMP for 24 hours without IPTG and replated the clones. Six out of ten BGAL-MOR clones resulted in a more robust β -gal stain *in situ* as compared to control "average" cells (BGALC1 and C2). We next performed a more quantitative assay using a β -gal ELISA assay. Briefly, 2 mls of cell centrifuged at 10,000gs for 10 minutes and resuspended in 0.5 mls of 0.25M Tris, pH 7.5 plus 0.0001% Tween-20. Cells were freeze-thawed 4X's and vortexed for 4 minutes at room temperature. Lysates were cleared of debris by centrifugation and supernatants were collected. Protein extracts were quantified for total protein using the Bradford assay (BioRad) as described by the manufacturer. Plate ELISAs were

carried out by coating 96 well maxisorb (NUNC) plates with 0.1 mls of a 1 µg/ml (diluted in PBS pH7.0) bacterial extract solution and a dose range of recombinant β-GAL (Sigma) from 0.001 to 10 mg/ml. All samples were plated in triplicates. Plates were coated for 2 hours, washed 2 times with PBS and blocked with 0.2mls of PBS plus 5% powdered milk for 30 minutes. Next, plates were washed once with PBS and incubated with an anti-β-galactosidase monoclonal antibody that recognizes both native and denatured forms (Sigma) for 2 hours. Plates were then washed 3 times with PBS and incubated with 0.1 mls of an anti-mouse horseradish peroxidase conjugated antibody for 1 hour at room temperature. Plates were washed 3 times with PBS and incubated with TMB ELISA substrate (BioRad) for 15 to 30 minutes. Reactions were stopped with 0.1N H₂SO₄ and read on a BioRAD plate reader at 415nm. The control clones produced roughly 9 and 13 µgs /ml of β-gal while BGAL-MOR clones 2, 3 and 9 produced 106, 82 and 143 µgs /ml of β-gal. To determine if reason that these clones produced more β-gal was due to mutations in the plasmid promoter elements, we isolated the pTLACZ plasmid and retransfected it into DH10B cells as described above. *In situ* analysis found the resultant clones to produce similar amount of β-gal as that of the control. These data suggest that the BGAL-MOR 2, 3, and 9 hosts had alterations, which results in elevated expression and/or stability of recombinant proteins.

To determine if the enhanced *in situ* β-gal expression that was observed in BGAL-MOR clones 1, 5, and 6, which did not appear to have enhanced β-gal protein levels (had less than 15 µg/ml as determined by ELISA) was authentic, we performed a more quantitative assay on these lines plus the BGAL-MOR 9, the BGALC1 and C2 lines as control. Cells containing an empty vector

(without a LACZ gene) were used as negative control. To measure β -gal activity, we employed a colorimetric β -gal substrate assay using CPRG (Roche) as described (31). Briefly, 5 μ g of protein extract isolated for ELISA analysis (described above) were analyzed using a plate assay. Protein was added to buffer containing 45 mM 2-mercaptoethanol, 1mM $MgCl_2$, 0.1 M $NaPO_4$ and 0.6 mg/ml Chlorophenol red- β -D-galactopyranoside (CPRG, Roche). Reactions were incubated for 1 hour, terminated by the addition of 0.5 M Na_2CO_3 , and analyzed by spectrophotometry at 576 nm in a BioRad plate reader. Analysis of these extracts confirmed our *in situ* data that these cells did have increased β -gal activity (TABLE 3).

TABLE 3. Generation of bacterial clones with increased β -gal enzymatic activity via MMR deficiency.

Clone	β -gal protein (μ g/ml)	β -gal activity (O.D. 576)
BGAL-C1	9	0.413 +/- .092
BGAL-C2	13	0.393 +/- .105
BGAL-MOR1	14	0.899 +/- .134
BGAL-MOR5	13	0.952 +/- .133
BGAL-MOR6	15	0.923 +/- .100
BGAL-MOR9	143	0.987 +/- .106
Empty vector	-	0.132 +/- .036

Because there was no observable increase in the amount of β -gal protein one likely hypothesis is that the β -gal gene structure was mutated during the hypermutability growth stage and now produces a

more active enzyme. Sequence analysis confirms that this may be the reason for enhanced activity in a subset of clones.

Together, these data demonstrate the ability to produce genetically altered prokaryotic host strains using dominant negative
5 MMR genes to generate commercially valuable output traits such as high recombinant protein producer lines and structurally altered enzymes with enhanced activities.

**EXAMPLE 4: Mutations in the host genome generated by
10 defective MMR are genetically stable**

As described in EXAMPLE 2 and 3, manipulation of the MMR pathway in microbes results in alterations within the host genome and the ability to select for a novel output traits. It is
15 important that the mutations introduced as a result of defective MMR is genetically stable and passed on to daughter cells once a desired output pathway is established. To determine the genetic stability of mutations introduced into the microbial genome the following experiment was performed. Five independent colonies from pT7-
20 PMS134 and pT7-PMSR3 that are kanamycin resistance were grown overnight from an isolated colony in 5 ml of LB. Next, 1 μ L of the overnight culture from these cultures were inoculated into another 5 mL of LB and grown overnight to saturation. Under these growth conditions the microbial cells have divided over 20 generations.
25 Therefore, if the new output trait generated by alteration of MMR is unstable, the cells should "revert" back from kanamycin resistance to kanamycin sensitivity. Cells were plated onto LB plates and incubated overnight at 37°C. Next, the colonies (about 1,000/plate) were replica plated to LB, LB^{amp¹⁰⁰}, and LB^{kan⁵⁰} plates and incubated
30 at 37°C overnight. Analysis of clones from these studies reveal that a

strict correlation occurs with loss of dominant negative MMR expression and phenotype stability. No loss of KAN resistant clones generated in Example 3 were observed when cells were grown in the absence of IPTG (not expressing PMS134), while 5 revertants out of 5 1200 were observed in clones the were continually grown in IPTG (express PMS134). Extended culturing of cells and replica plating found no reversions of KAN resistance in cultures grown in the absence of IPTG, which produce no PMS134 as determined by western blot (data not shown).

10 These data demonstrate the utility of employing inducible expression systems and dominant negative MMR genes in prokaryotes to generate genetically altered strains for commercial applications such as but not limited to enhanced recombinant manufacturing and biotransformation that can then in turn be restored 15 to a genetically stable host with a "fixed" new genotype that is suitable for commercial processes.

EXAMPLE 5: Enhanced Generation of MMR-Defective Bacteria and Chemical Mutagens for the Generation of New Output

20 Traits

It has been previously documented that MMR deficiency yields to increased mutation frequency and increased resistance to toxic effects of chemical mutagens (CM) and their respective analogues such as but not 25 limited to those as: ethidium bromide, EMS, MNNG, MNU, Tamoxifen, 8-Hydroxyguanine, as well as others listed but not limited to in publications by: Khromov-Borisov, N.N., et.al. (Mutat. Res. 430:55-74, 1999); Ohe, T., et.al. (Mutat. Res. 429:189-199, 1999); Hour, T.C. et.al. (Food Chem. Toxicol. 37:569-579, 1999); Hrelia, P., et.al. (Chem. Biol. Interact. 118:99- 30 111, 1999); Garganta, F., et.al. (Environ. Mol. Mutagen. 33:75-85, 1999);

Ukawa-Ishikawa S., et.al. (Mutat. Res. 412:99-107, 1998);
www.ehs.utah.edu/ohh/mutagens, etc. To demonstrate the ability of CMs
to increase the mutation frequency in MMR defective bacterial cells, we
exposed T7-PMS134 BL21 cells to CMs.

- 5 T7-PMS134 cells and empty vector control cells were grown with
IPTG for 48 hours and then diluted 1: 50 in LB plus IPTG and increasing
amounts of ethyl methane sulfonate (EMS) from 0, 1, 10, 50, 100, and 200
 μM . 10 μL aliquots of culture (diluted in 300 μL LB) were plated out on
LB agar plus ampicillin plates and grown overnight at 37C. The next day
10 plates were analyzed for cell viability as determined by colony formation.
Analysis found that while no significant difference in colony number was
observed between the pT7-PMS134 and control at the 0, 1, or 10 μM
concentrations (all had > 1000 colonies), the number of control cells were
reduced to 30 and 0 at the 50 and 100 μM concentrations, respectively. No
15 difference was observed in the pT7-PMS134 cells treated with 0, 1, 10 or
50 μM , while a 3 fold reduction was observed in cultures treated with 100
 μM EMS. The 200 μM treatment was toxic for both lines. These data
demonstrate the ability of MMR deficiency to protect prokaryotes against
the toxic effects of DNA alkylating agents and provides a means to generate
20 a wider range of mutations that can lead to an increased number of genetic
variations and an increase in the number of new biochemical activities
within host proteins to produce new output traits for commercial
applications.

- To confirm that MMR deficient bacterial cells treated with CM can
25 result in an increased mutation rate and produce a greater number of
variants, we cultured pT7-PMS134 cells and empty vector controls in the
presence of IPTG for 48 hours, followed by dilution and regrowth in 25 μM
EMS for 24 hours as described above. Cells were plated out on 100 mM
petri dishes containing ampicillin or KAN and scored for KAN resistance.
30 Analysis revealed that an 11-fold increase in the generation of KAN

resistant cells were found in pT7-Ea-PMS134V5 cells in contrast to control cells.

These data demonstrate the use of employing a regulated dominant negative MMR system plus chemical mutagens to produce enhanced numbers of genetically altered prokaryotic strains that can be selected for new output traits. This method is now useful for generating such organisms for commercial applications such as but not limited to recombinant manufacturing, biotransformation, and altered biochemicals (biotransformation) with enhanced activities for manufacturing purposes and gene discovery for pharmaceutical compound development.

EXAMPLE 6: Alternative Methods to Inhibition of Bacterial MMR Activity

The inhibition of MMR activity in a host organism can be achieved by introducing a dominant negative allele as shown in EXAMPLES 2 and 3. This application also teaches us the use of using regulated systems to control MMR in prokaryotes to generate genetic diversity and output traits for commercial applications. Other ways to regulate the suppression of MMR activity of a host is by using genetic recombination to knock out alleles of a MMR gene that can be spliced out such as after selection using a system such as the CRE-Lox system; 2) blocking MMR protein dimerization with other subunits (which is required for activity) by the introduction of polypeptides or antibodies into the host via transfection methods routinely used by those skilled in the art; or 3) decreasing the expression of a MMR gene using anti-sense oligonucleotides.

MMR gene knockouts. We intend to generate disrupted targeting vectors of a particular MMR gene and introduce it into the genome of bacteria using methods standard in the art. Bacteria exhibiting hypermutability will be useful to produce genetically diverse offspring for commercial applications.

Bacteria will be confirmed to have lost the expression of the MMR gene using standard northern and biochemical techniques (as described in reference 32). MMR gene loci can be knocked out, strains selected for new output traits and MMR restored by introducing a wildtype MMR gene to
5 complement the KO locus. Other strategies include using KO vectors that can target a MMR gene locus, select for host output traits and then have the KO vector "spliced" from the genome after strain generation. This process could be performed using systems such as but not limited to CRE-Lox.

10 Blocking peptides. MMR subunits (MutS and MutL proteins) interact to form active MMR complexes. Peptides are able to specifically inhibit the binding of two proteins by competitive inhibition. The use of peptides or antibodies to conserved domains of a particular MMR gene can be introduced into prokaryotic cells using lipid transfer methods that are
15 standard in the art. Bacteria will be confirmed to have lost the expression of the MMR gene using standard northern and biochemical techniques (as described in reference 32). Bacteria exhibiting hypermutability will be useful to produce genetically diverse sibs for commercial applications.

20 Discussion

The results described above will lead to several conclusions. The expression of dominant negative MMR proteins results in an increase in hypermutability in bacteria. This activity is due to the inhibition of MMR biochemical activity in these hosts. This method provides a claim for use of
25 dominant negative MMR genes and their encoded products for the creation of hypermutable bacteria to produce new output traits for commercial applications.

EXAMPLES OF MMR GENES AND ENCODED POLYPEPTIDES

Yeast MLH1 cDNA (accession number U07187)

5 1 aaataggaat gtgatacctt ctattgcatg caaagatagt gtaggaggcg ctgctattgc
 61 caaagacttt tgagaccgct tgctgtttca ttatagtgtg ggagttctcg aagacgagaa
 121 attagcagtt ttcgggtgtt agtaatcgcg ctagcatgct aggacaattt aactgcaaaa
 181 ttttgatagc atagtgtatg taaatggaag gtaaaaataa catagacctt tcaataagca
 241 atgtctctca gaataaaagc acttgatgca tcagtgggta acaaaattgc tgcaggtgag
 10 301 atcataatat cccccgtaaa tgctctcaaa gaaatgatgg agaattccat cgatgcgaat
 361 gctacaatga ttgatattct agtcaaggaa ggaggaatta aggtacttca aataacagat
 421 aacggatctg gaattaataa agcagacctg ccaatcttat gtgagcgatt cacgacgtcc
 481 aaattacaaa aattcgaaga tttgagtcag attcaaacgt atggattccg aggagaagct
 541 ttagccagta tctcacatgt ggcaagagtc acagtaacga caaaagttaa agaagacaga
 15 601 tgtgcatgga gagtttcata tgcaagaagg aagatgttgg aaagcccaaa acctgttgct
 661 ggaaaagacg gtaccacgat cctagtgtga gacctttttt tcaatattcc ttctagatta
 721 agggccttga ggccccataa tgatgaatac tctaaaatat tagatgttgt cgggcgatac
 781 gccatttcatt ccaaggacat tggcttttct tgtaaaaagt tcggagactc taattattct
 841 ttatcagtta aaccttcata tacagtcacg gataggatta ggactgtgtt caataaatct
 20 901 gtggccttga atttaattac tttctatctc agcaaatgag aagatttaaa cctggaaaagc
 961 gttgatggaa aggtgtgtta tttgaatttc atatccaaaa agtccatttc attaattttt
 1021 ttcattaata atagactagt gacatgtgat cttctaagaa gagctttgaa cagcgtttac
 1081 tccaattatc tgccaaaagg cttcagacct tttatttatt tgggaattgt tatagatccg
 1141 gcggtctgtg atgttaacgt tcacccgaca aagagagagg ttcgtttcct gagccaagat
 25 1201 gagatcatag agaaaatcgc caatcaattg cacgccgaat tatctgccat tgatacttca
 1261 cgtactttca aggctttctc aatttcaaca aacaagccag agtcattgat accatttaat
 1321 gacaccatag aaagtgtatg gaataggaag agtcctccgac aagcccaagt ggtagagaat
 1381 tcataataca cagccaatag tcaactaagg aaagcgaaaa gacaagagaa taaaactagtc
 1441 agaatagatg cttcacaagc taaaattacg tcatttttat cctcaagtca acagttcaac
 30 1501 tttgaaggat cgtctacaaa gcgacaactg agtgaaccca aggtaacaaa tgtaaagccac
 1561 tcccaagagg cagaaaagct gacactaaat gaaagcgaaac aaccgcgtga tgccaataca
 1621 atcaatgata atgacttgaa ggatcaacct aagaagaaac aaaagtgtgg ggattataaa
 1681 gttccaagca ttgccgatga cgaaaagaat gcactcccgga tttcaaaaaga cgggtatatt
 1741 agagtaccta aggagcgagt taatgttaat cttacgagta tcaagaaatt gcgtgaaaaa
 35 1801 gtagatgatt cgatacatcg agaactaaca gacatttttg caaatgtgaa ttacgttggg
 1861 gttgtagatg aggaaaagag attagccgct attcagcatg acttaaaagt ttttttaata
 1921 gattacggat ctgtgtgcta tgagctatlc tatcagattg gtttgacaga cttcgcaaac
 1981 tttggttaaga taaacctaca gagtacaaat gtgtcagatg atatagtttt gtataatctc
 2041 ctatcagaat ttgacgagtt aaatgacgat gcttccaaag aaaaaataat tagtaaaata
 40 2101 tgggacatga gcagtatgct aatgagtagc tattccatag aatgtgtgaa tgatgttcta
 2161 gataatgact taaagtctgt gaagctaaaa tctctaccac tacttttaaa aggctacatt
 2221 ccatctctgg tcaagtctac attttttata tatcgccctg gtaaaagaat tgattgggag
 2281 gatgaacaag agtgtctaga tggtatttta agagagattg cattactcta tatacctgat
 2341 atgggtccga aagtcgatac actcgatgca tcgttgtcag aagacgaaaa agcccgattt
 45 2401 ataaatagaa aggaaacacat atcctcatta ctagaacacg ttctctcccc ttgtatcaaa
 2461 cgaagggttc tggcccttag acacattctc aaggatgtcg tggaatatgc caaccttcca
 2521 gatctataca aagtttttga gaggtgttaa ctttaaaacg ttttgctgtg aataccaaaq
 2581 tttttgttta tttcttgagt gtgatttgtt ttcatttgaa agtgtatgcc ctttccttta
 2641 acgattcatc cgcgagattt caaaggatat gaaatatggt tgcagttagg aaagtatgtc
 50 2701 agaaatgtat attcggattg aaactcttct aatagttctg aagtcacttg gttccgtatt
 2761 gttttcgtcc tcttctctca gcaacgattc ttgtctaaag ttattcaacg gtaccaaaaga
 2821 cccagatcct tttatgagag aaaacatttc atcatttttc aactcaatta tcttaatatc
 2881 atttttagat attttgaaaa caggatggta aaacgaatca cctgaatcta gaagctgtac
 2941 cttgtcccat aaaagtttta atttactgag cctttcggtc aagtaaaacta gtttatctag
 55 3001 ttttgaaccg aatattgtgg gcagatttgc agtaagttca gttagatcta ctaaaagtgt
 3061 tttgacagca gccgattcca caaaaatttg gtaaaaggag atgaaagaga cctcgcgcgt
 3121 aatggtttgc atcaccatcg gatgtctgtt gaaaaactca ctttttgcat ggaagtattt
 3181 aacaataaga ctaattgatta ccttagaata atgtataa

60 Yeast MLH1 protein (accession number U07187)

MSLRKALDASVVNKIAAGEIIISPVNALKEMMENSIDANATMI
 65 DILVKEGGIKVLQITDNGSGINKADLPILCERFTTSKLOKFEDLSQIQTYGFRGEALA
 SISHVARVTVTTKVKEDRCARVSYAEGKMLESPPKPVAGKDGTTIILVEDLFFNIPSR
 RALRSHNDEYSKILDVVGRYAIHSDKIGFSCKKFGDSNYSLSVKPSYTVQDRIRTVFN
 70 KSVASNLITFHISKVEDLNLESVDGKVCNLFISKKSISLIFFINNRLVTCDLLRRAL
 NSVYSNYLPKGRPFYILGIVIDPAVDVNVHPTKREVRFLSQDEIIEKIANQLHAEL
 SAIDTSRTFKASSISTNKPESLIPFNDTIESDRNRKSLRQAQVENSYTTANSQRLKA

5 KRQENKLVRIDASQAKITSFLSSSQQNFEGSSTKRQLSEPKVTNVSHSQAEKLTN
 ESEQPRDANTINONDLKDQPKKKQKLGDYKVPISADDEKNALPISKDGYIRVPKERVN
 10 VNLTSIKKLREKVDSIHRELTDIFANLNYGVVDEERRLAHQHDLKFLIDYGSVC
 YELFYQIGLTDFAFGKINLQSTNVSDDIVLYNLLSEFDELNDASKEKIISKIWDMS
 SMLNEYYSIELVNDGLDNDLKSVLKSLFLLKGYIPSLVKLPFFIYRLGKEVDWEDE
 QECLDGILREIALLYIPDMVPKVDTLDAASLSEDEKAQFINRKEHISLLEHVLFPCKI
 15 RRFLAPRHILKDVVEIANLPDLYKVFERC

Mouse PMS2 protein

MEQTEGVSTE CAKAIKPIDG KSVHQICSGQ VILSLSTAVK ELIENSVDAG ATTIDRLKD 60
 YGVDLIEVSD NGCGVEEENF EGLALKHHTS KIQEFADLTQ VETFGFRGEA LSSLCALSDV 120
 TISTCHGSAS VGTRLVFDHN GKITQKTPYP RPKGTTVSQV HLFYTLFVRY KEFQRNIKKE 180
 20 YSKMVQVLQA YCIISAGVRV SCTNQLGQK RHAVVCTSGT SGMKENIGSV FGQKQLQSLI 240
 PFVQLPPSDA VCEEYGLSTS GRHKTFTSTR ASFHSARTAP GGVQQTGSFS SSIRGPVTQQ 300
 RSLSLSMRFY HMYNRHQYFF VVLNVSDSE CVDINVTDPK RQILLQEEKL LLAVLKTSLI 360
 GMFDSANKL NVNQQLLELV EGNLVKLHTA ELEKPVPGKQ DNSPSLKSTA DEKRVASISR 420
 LREAFSLHPT KEIKSRGPET AELTRSPSE KRGVLSSYPS DVISYRGLRG SQDKLVSPDT 480
 25 SPGDCMDREK IEKDSGLSST SAGSEEFST PEVASSFSSD YNVSSLEDRP SQETINCGDL 540
 DCRPPGTGQS LKPEDHGYQC KALPLARLSP TNAKRFTKEE RPSNVNISQR LPGPOSTSAA 600
 EVDVAIKMNK RIVLLEFSL SIAKRMKQLQ HLKAQNKHEL SYRKFRKIC PGENQAAEDE 660
 LRKEISKSMF AEMEILGQFN LGFIVTKLKE DLFLVDQHAA DEKYNFEMLO QHTVLQAQRL 720
 ITPQTINLTA VNEAVLIENL EIFRKNGFDF VIDEAPVTE RAKLISLPTS KNWTFGFQDI 780
 30 DELIFMLSDS PGVMCRPSRV RQMFASRACR KSMIGTALN ASEMKKLITH MGEMDHPWNC 840
 PHGRPTMRHV ANLDVISQN
 859

Mouse PMS2 cDNA

35 gaattccggt gaaggtcctg aagaatttcc agattcctga gtatcattgg aggagacaga 60
 taacctgtcg tcaggttaacg atggtgtata tgcaacagaa atgggtgttc ctggagacgc 120
 gtcttttccc gagagcggca ccgcaactct cccgcggtga ctgtgactgg aggagtcctg 180
 catccatgga gcaaaccgaa ggcgtgagta cagaatgtgc taaggccatc aagcctattg 240
 atgggaagtc agtccatcaa attgttctg ggcaggtgat actcagtta agcaccgctg 300
 40 tgaaggagtt gatagaaaat agttagatg ctggtgctac tactattgat ctaaggctta 360
 aagactatgg ggtggacctc attgaagttt cagacaatgg atgtggggtg gaagaagaaa 420
 actttgaagg tctagctctg aaacatcaca catctaagat tcaagagttt gccgacctca 480
 cgcaggttga aactttcggc ttccgggggg aagctctgag ctctctgtgt gcaactaagt 540
 atgtcactat atctacctgc caccggtctg caagcgttgg gactcgactg gtgtttgacc 600
 45 ataatgggaa aatcaccag aaaactccct acccccgacc taaaggaaacc acagtcaagt 660
 tgcagcactt atttatata ctaccctgc gttacaaaga gtttcagagg aacattaaaa 720
 aggagtattc caaaatggtg caggtcttac aggcgtactg tatcatctca gcaggcgctc 780
 gtgtaagctg cactaatcag ctccgacagg ggaagcgcca cgctgtggtg tgcacaagcg 840
 gcacgtctgg catgaaggaa aatatcggtt ctgtgtttgg ccagaagcag ttgcaaaagg 900
 50 tcattccctt tgttcagctg cccctagtg acgctgtgtg tgaagagtag gccctgagca 960
 cttcaggacg ccacaaaacc tttctacgt ttcgggcttc attcacagt gcacgcacgg 1020
 cgccgggagg agtgcaacag acaggcagtt tttcttcac aatcagaggc cctgtgacct 1080
 agcaaaagtc tctaagctt tcaatgaggt tttatcacat gtataaccgg catcagtacc 1140
 catttgcgt ccttaacgtt tccgttgact cagaatgtgt ggatattaat gtaactccag 1200
 55 ataaaaggca aattctacta caagaagaga agctattgct ggccgtttta aagacctcct 1260
 tgataggaat gtttgacagt gatgcaaca agcttaatgt caaccagcag ccactgctag 1320

atgttgaagg taacttagta aagctgcata ctgcagaact agaaaagcct gtgccaggaa 1380
 agcaagataa ctctccttca ctgaagagca cagcagacga gaaaagggtta gcatccatct 1440
 ccaggctgag agaggccttt tctcttcac ctactaaaga gatcaagtct aggggtccag 1500
 5 agactgctga actgacacgg agttttccaa gtgagaaaag gggcgtgtta tctctttac 1560
 cttcagacgt catctcttac agaggcctcc gtggtctgca ggacaaattg gtgagtccca 1620
 cggacagccc tgggtactgt atggacagag agaaaataga aaaagactca gggctcagca 1680
 gcacctcagc tggctctgag gaagagttca gcacccacga agtggccagt agcttttagca 1740
 gtgactataa cgtgagctcc ctagaagaca gaccttctca ggaaaccata aactgtggtg 1800
 acctggactg ccgtcctcca ggtacaggac agtccttgaa gccagaagac catggatata 1860
 10 aatgcaaaagc tctacctcta gctcgtctgt caccacacaa tgccaagcgc ttcaagacag 1920
 aggaagagacc ctcaaatgtc aacattttctc aaagattgcc tggctctcag agcacctcag 1980
 cagctgaggt cgtatgtagc ataaaaatga ataagagaat cgtgctcctc ggtttctctc 2040
 tgagttctct agctaagcga atgaagcagt tacagcacct aaaggcgcag aacaaacatg 2100
 aactgagtta cagaaaattt agggccaaga tttgccctgg agaaaaccaa gcagcagaag 2160
 15 atgaactcag aaaagagatt agtaaatcga tgtttgcaga gatggagatc ttgggtcagt 2220
 ttaacctggg atttatagta accaaactga aagaggacct cttcctggtg gaccagcatg 2280
 ctgctgatga gaagtacaac tttgagatgc tgcagcagca caggtgctc caggcgcaga 2340
 ggctcatcac accccagact ctgaacttaa ctgctgtcaa tgaagctgta ctgatagaaa 2400
 20 atctggaat attcagaaaag aatggctttg actttgtcat tgatgaggat gctccagtca 2460
 ctgaaagggc taaattgatt tctttaccaa ctagtaaaa ctggaccttt ggacccaag 2520
 atatatagta actgatcttt atgttaagtg acagccctgg ggtcatgtgc cggccctcac 2580
 gagtcagaca gatgtttgct tccagagcct gtccgaagtc agtgatgatt ggaacggcgc 2640
 tcaatgcgag cgagatgaag aagctcatca cccacatggg tgagatggac caccctgga 2700
 actgccccca cggcaggcca accatgaggc acgttgccaa tctggatgc atctctcaga 2760
 25 actgacacac cctttgtagc atagagtta ttacagattg ttcggtttgc aaagagaagg 2820
 ttttaagtta tctgattatc gttgtacaaa aattagcatg ctgctttaat gtactggatc 2880
 catttaaaag cagtgttaag gcaggcatga tggagtgttc ctctagctca gctacttggg 2940
 tgatccggtg ggagctcatg tgagccagg actttgagac cactccgagc cacattcatg 3000
 30 agactcaatt caaggacaaa aaaaaaaga tatttttgaa gccttttaaa aaaaaa 3056

 human PMS2 protein
 MKQLPAATVR LLSSSQIITS VVSUVKELIE NSLDAGATSV DVKLENYGFD KIEVRDNGEG 60
 IKAVDAPVMA MKYYTSKINS HEDLENLTTY GFRGEALGSI CCIAEVLITT RTAADNFSTQ 120
 YVLDGSGHIL SQKPSHLGQG TTVTALRLFK NLPVRKQFYS TAKKCKDEIK KIQDLLMSFG 180
 35 ILKPDRLRIV VHNKAVIWQK SRVSDHKMAL MSVLGTAVMN NMESFQYHSE LSQIYLSGFL 240
 PKCDADHSFT SLSTPERSFI FINSRPVHOK DILKLIRHHY NLKCLKESTR LYPVFFLKID 300
 VPTADVVDNL TPDKSQVLLQ NKESVLIALE NLMTTCYGPL PSTNSYENNK TDVSAADIVL 360
 SKTAETDVLV NKVESSGKNY SNVDTSVIFP QNDMHNDESG KNTDDCLNHQ ISIGDFGYGH 420
 CSSEISNIDK NTKNAFQDIS MSNVSWENSQ TEYSKTCFIS SVKHTQSENG NKDHIDESGE 480
 40 NEEAEGLENS SEISADEWSR GNILKNSVGE NIEPVKILVP EKSLPCKVSN NNYPIPEQMN 540
 LNEDSCNKKs NVIDNKSGKV TAYDLSNRV IKKPMASAL FVQDHRPQFL IENPKTSLED 600
 ATLQIEELWK TLSEEEKLKY EEKATKDLER YNSQMKRAIE QESQMSLKDG RKKIKPTSAS 660
 NLAQKHKLKT SLSNQPKLDE LLQSIEKRR SQNIKMVQIP FSMKNLKINF KKQNKVDLEE 720
 KLEPCLIHNL RFPDANLMTS KTEVLLNPNY RVEEALLFKR LLENHKLPAE PLEKPIMLTE 780
 45 SLFNGSHYLD VLYKMTADDQ RYSGSTYLSL PRLTANGFKI KLIPGVSITE NYLEIEGMAN 840
 CLPFYGVADL KEILNAILNR NAKEVYECRP RKVISYLEGE AVRLSRQLPM YLSKEDIQDI 900
 IYRMKHQFGN EIKECVHGRP FFHHLTYLPE TT 932

5 Human PMS2 cDNA
 cgaggcggat cgggtgttgc atccatggag cgagctgaga gctcgagtac agaacctgct 60
 aaggccatca aacctattga tcggaagica gtccatcaga ttgtctcttg gcagggtgga 120
 ctgagtctaa gcaactgcgg aaaggagtta gtgaaaaaca gtctggatgc tgggtccact 180
 aatattgac taaagcttaa ggactatgga gtggatctta ttgaagtctc agacaatgga 240
 10 tgtggggtag aagaagaaaa cttcgaaggc ttaactctga aacatcacac atctaagatt 300
 caagagtctg ccgacctaac tcagggttgaa acttttggtc ttccggggga agctctgagc 360
 tcactttgtg cactgagcga tgtcaccatt tctacctgcc acgcctcggc gaaggttgga 420
 actcgactga tgtttgatca caatgggaaa attatccaga aaacccccct ccccccccc 480
 agagggaaca cagtcagcgt gcagcagtta tttccacac tacctgtgcg ccataaggaa 540
 15 tttcaaggaa atattaagaa ggagtatgcc aaaatggtcc aggtcttaca tgcatactgt 600
 atcatttcag caggcatccg tgtaagtgc accaatcagc ttggacaagg aaacgacag 660
 cctgtggtat gcacagggtg aagccccagc ataaaggaaa atatcggtc tgtgtttggg 720
 cagaagcagt tgcaaacgct cattcctttt gttcagctgc cccctagtga ctccgtgtgt 780
 gaagagtacg gtttgagctg ttcggatgct ctgcataatc tttttacat ctccagtttc 840
 20 atttcacaat gcacgcagtg agttggaagg agttcaacag acagacagtt tttctttatc 900
 aaccggcggc cttgtgaccc agcaagggtc tgcagactcg tgaatgaggt ctaccacatg 960
 tataatcgac accagtatcc atttgttgtt cttaacattt ctgttgattc agaatgcgtt 1020
 gatataatg ttactccaga taaaaggcaa attttgctac aaggaggaaa gcttttgttg 1080
 gcagttttaa agacctcttt gataggaatg tttgatagt atgtcaacaa gctaaatgtc 1140
 25 agtcagcagc cactgctgga tgttgaagg aacttaataa aaatgcatgc agcggatttg 1200
 gaaaagccca tggtagaaa gcaggatcaa tccccctcat taaggactgg agaagaaaaa 1260
 aaagacgtgt ccatttccag actgcgagag gccttttctc ttcgtcacac aacagagaaa 1320
 aagcctcaca gcccaagac tccagaacca agaaggagcc ctctaggaca gaaaaggggt 1380
 atgctgtctt ctagcacttc aggtgccatc tctgacaaag gcgtcctgag acctcagaaa 1440
 30 gaggcagtga gttccagtca cggaccaggt gacctacgg acagagcgga ggtggagaag 1500
 gactcggggc acggcagcac ttccgtggat tctgaggggt tcagcatccc agacacgggc 1560
 agtcactgca gcagcagta tgcggccagc tcccagggg acaggggctc gcaggaaatc 1620
 gtggactctc aggagaaagc gcctgaaact gacgactctt tttcagatgt ggactgccat 1680
 tcaaaccagg aagataccgg atgtaaattt cgagttttgc ctacgccaac taatctcgca 1740
 35 accccaaaca caaagcgttt taaaaagaa gaaattcttt ccagttctga catttgtcaa 1800
 aagttagtaa atactcagga catgtcagcc tctcaggttg atgtagctgt gaaaattaat 1860
 aagaaagttg tgccccgga cttttctatg agttctttag ctaaacgaat aaagcagtta 1920
 catcatgaag cacagcaaag tgaaggggaa cagaattaca ggaagtttag ggcaagatt 1980
 tgcctggag aaaaatcaagc agccgaagat gaactaagaa aagagataag taaaacgatg 2040
 40 ttgcagaaa tggaaatcat tggtcagttt aacctgggat ttataataac caaactgaat 2100
 gaggatattc tcatagtgga ccagcatgcc acggacgaga agtataactt cgagatgctg 2160
 cagcagcaca ccgtgctcca ggggcagagg ctcatagcac ctgagactct caacttaact 2220
 gctgttaatg aagctgttct gatagaaaat ctggaatat ttgaaagaa tggctttgat 2280
 tttgttatcg atgaaaatgc tccagtcact gaaagggcta aactgatttc ctgccaact 2340
 45 agtaaaaact ggaccttcgg accccaggac gtcgatgaac tgatcttcat gctgagcgac 2400
 agccctgggg tcatgtgccg gccttcccga gtcaagcaga tgtttgcctc cagagcctgc 2460
 cggaaagtcg tgatgattgg gactgctctt aacacaagcg agatgaagaa actgatcacc 2520
 cacatggggg agatggacca cccctggaac tgtcccatg gaaggccaac catgagacac 2580
 atcgccaacc tgggtgtcat ttctcagaac tgaccgtagt cactgtatgg aataattggt 2640

tttatcgag atttttatgt ttgaaagac agagtcttca ctaacctttt ttgttttaa 2700
 atgaaacctg ctacttaaaa aaaatacaca tcacacccat ttaaaagtga tcttgagaac 2760
 cttttcaaac c
 2771

5

human PMS1 protein

5
 10
 15
 20
 25
 30
 35
 40
 45

human PMS1 protein

MKQLPAATVR LLSSSQIITS VVSVKELIE NSLDAGATSV DVKLENYGFD KIEVRDNGEG 60
 IKAVDAPVMA MKYYTSKINS HEDLENLTYY GFRGEALGSI CCIAEVLITT RTAADNFSTQ 120
 YVLDSGSHIL SQKPSHLGQG TTVTALRLFK NLPVRKQFYS TAKKCKDEIK KIQDLLMSFG 180
 ILKPDLRIVF VHNKAVIWQK SRVSDHKMAL MSVLGTAVMN NMESFOYHSE ESQIYLSGFL 240
 PKCADHSFT SLSTPERSFI FINSRPVHQK DILKLIRHHY NLKCLKESTR LYPVFFLKID 300
 VPTADVVDNL TPKDSQVLLQ NKESVLIALE NLMTTCYGPL PSTNSYENNK TDVSAADIVL 360
 SKTAETDVLV NKVESSGKNY SNVDTSVIPF QNDMHNDESG KNTDDCLNHQ ISIGDFGYGH 420
 CSSEISNIDK NTKNAFQDIS MSNVSWNSQ TEYSKTCFIS SVKHTQSENG NKDHIDESGE 480
 NEEEAAGLENS SEISADEWSR GNILKNSVGE NIEPVKILVP EKSLPCKVSN NNYPEIQMN 540
 LNEDSCNKKs NVIDNKGKV TAYDLSNRV IKKPMASAL FVQDHRPQFL IENPKTSLED 600
 ATLOIEELWK TLSEEEKLY EEKATKDLER YNSQMRAIE QESQMSLKDG RKKIKPTS AW 660
 NLAQKHKLKT SLSNQPKLDE LLQSQIEKRR SQNIKMVQIP FSMKNLKINF KKQNKVDLEE 720
 KDEPCLIHNL RFPDAWLMTS KTEVMLNPFY RVEEALLFKR LLENHKLPAE PLEKPIMLTE 780
 SLFNGSHYLD VLYKMTADDQ RYSGSTYLSL PRLTANGFKI KLIPGVSITE NYLIEIGMAN 840
 CLPFYGVADL KEILNAILNR NAKEVYECRP RKVISYLEGE AVRLSRQLPM YLSKEDIODI 900
 IYRMKHQFGN EIKECVHGRP FFHHLTYLPE TT
 932

Human PMS1 cDNA

5
 10
 15
 20
 25
 30
 35
 40
 45

Human PMS1 cDNA

ggcagcagtg gctgcttgcg gctagtggat ggtaattgcc tgcctcgcg tagcagcaag 60
 ctgctctggt aaaagcgaaa atgaaacaat tgcctgcggc aacagttcga ctcttttcaa 120
 gttctcagat catcacttcg gtggtcagtg ttgtaaaaga gcttattgaa aactccttgg 180
 atgctggtgc cacaagcgta gatgttaaac tggagaacta tggatttgat aaaattgagg 240
 tgcgagataa cggggagggt atcaaggctg ttgatgcacc tgtaattgca atgaagtact 300
 acacctcaaa aataaatagt catgaagatc ttgaaaattt gacaacttac ggttttcgtg 360
 gagaagcctt ggggtcaatt tgtgtatag ctgaggtttt aattacaaca agaacggctg 420
 ctgataattt tagcaccag tatgttttag atggcagtg ccacatactt tctcagaaac 480
 cttcacatct tggtaagggt acaactgtaa ctgctttaag attatttaag aatctacctg 540
 taagaaagca gttttactca actgcaaaaa aatgtaaaga tgaaataaaa aagatccaag 600
 atctctcat gagctttggt atccttaaac ctgacttaag gattgtctt gtacataaca 660
 aggcagttat ttggcagaaa agcagagtat cagatcaca gatggctctc atgtcagttc 720
 tggggactgc tgttatgaac aatatggaat cctttcagta ccactctgaa gaatctcaga 780
 tttatctcag tggatttctt ccaaagtgtg atgcagacca ctctttcact agtctttcaa 840
 caccagaaaag aagtttcac ttcataaaca gtcgaccagt acatcaaaaa gatattctaa 900
 agttaatccg acatcattac aatctgaaat gcctaaagga atctactcgt ttgtatcctg 960
 ttttctttct gaaaatcgat gttcctacag ctgatgttga tgtaaattta acaccagata 1020
 aaagccaagt attattacaa aataaggaat ctgttttaat tgctcttgaa aatctgatga 1080
 cgacttgta tggaccatta cctagtacaa attcttatga aaataataaa acagatgttt 1140
 ccgcagctga catcgctctt agtaaaacag cagaaacaga tgtgcttttt aataaaagtg 1200
 aatcatctgg aaagaattat tcaaatgttg atacttcagt cattccattc caaaatgata 1260
 tgcataatga tgaatctgga aaaaacactg atgattgttt aaatcaccag ataagtattg 1320
 gtgactttgg ttatggtcat tgtagtagtg aaatttctaa cattgataaa aacactaaga 1380

atgcatttca ggacatttca atgagtaatg tatcatggga gaactctcag acggaatata 1440
 gtaaaacttg ttttataagt tccgttaagc acaccagtc agaaaatggc aataaagacc 1500
 atatatagta gagtggggaa aatgagggaag aagcaggtct tgaaaactct tcggaatttt 1560
 ctgcagatga gtggagcagg ggaatatac ttaaaaattc agtgggagag aatattgaac 1620
 5 ctgtgaaaat tttagtgcct gaaaaaagtt taccatgtaa agtaagtaat aataattatc 1680
 caatccctga acaaatgaat cttaatgaag attcatgtaa caaaaaatca aatgtaatat 1740
 ataataaatc tggaaaagtt acagcttatg atttacttag caatcgagta atcaagaaac 1800
 ccatgtcagc aagtgcctct tttgttcaag atcatcgctc tcagtttctc atagaaaaac 1860
 ctaagactag tttagaggat gcaacactac aaattgaaga actgtggaag acattgagtg 1920
 10 aagaggaaaa actgaaatat gaagagaagg ctactaaaga ctggaacga tacaatagtc 1980
 aaatgaagag agccattgaa caggagtcac aaatgtcact aaaagatggc agaaaaaaga 2040
 taaaacccac cagcgcatgg aatttggccc agaagcacaa gttaaaaacc tcattatcta 2100
 atcaaccaaa acttgatgaa ctcttcagt cccaaattga aaaaagaagg agtcaaaata 2160
 ttaaaatggt acagatcccc tttctatga aaaacttaaa aataaatttt aagaaacaaa 2220
 15 acaaagtga cttagaagag aaggatgaac ctgtcttgat ccacaatctc aggtttcctg 2280
 atgcattgct aatgacatcc aaacagagg taatgttatt aaatccatat agagtagaag 2340
 aagccctgct atttaaaaga ctctctgaga atcataaact tctgcagag ccaactggaa 2400
 agccaattat gttaacagag agtcttttta atggatctca ttatttagac gttttatata 2460
 aaatgacagc agatgaccaa agatagctg gatcaactta cctgtctgat cctcgtctta 2520
 20 cagcgaatgg tttcaagata aaattgatac caggagtctt aattactgaa aattacttgg 2580
 aaatagaagg aatggctaatt tgtctccat tctatggagt agcagattta aaagaaattc 2640
 ttaatgctat attaaacaga aatgcaaagg aagtttatga atgtagacct cgcaaagtga 2700
 taagtatttt agaggagaa gcagtcgctc tatccagaca attaccatg tacttatcaa 2760
 aagaggacat ccaagacatt atctacagaa tgaagcacca gtttggaat gaaattaaag 2820
 25 agtgtgttca tggtcgccc tttttctatc atttaacctt tcttcagaa actacatgat 2880
 taaatatggt taagaagatt agttaccatt gaaattggt ctgcatata acagcatgag 2940
 tctggtttta aattatcttt gtattatgtg tcacatggtt attttttaa tgaggattca 3000
 ctgactgtt tttatattga aaaaagtcc acgtattgta gaaaacgtaa ataaactaat 3060
 aac 3063
 30

human MSH2 protein
 MAVQPKETLQ LESAAEVGFV RFFQGMPEKP TTVRLFDRG DFYTAHGEDA LLAAREVFKT 60
 QGVIKYMGPA GAKNLQSVVL SKMNFESFVK DLLLVRYRV EVYKNRAGNK ASKENDWYLA 120
 35 YKASPGNLSQ FEDILFGNND MSASIGVVG VMSAVDQQRQ VGVGYVDSIQ RKLGLCLFPD 180
 NDQFSNLEAL LIQIGPKCV LPGGETAGDM GKLRQIIQRG GILITERKKA DFSTKDIYQD 240
 LNRLLKGGKG EQMNSAVLPE MENQVAVSSL SAVIKFLELL SDDSNFGQFE LTTFDFSQYM 300
 KLDIAAVRAL NLFQGSVEDT TGSQSLAALL NKCKTPQGQR LVNQWIKQPL MDKNRIEERL 360
 NLVEAFVEDA ELRCTLQEDL LRRFPDLNRL AKKFQRQAAN LQDCYRLYQG INQLPNVIQA 420
 40 LEKHEGKHOK LLLAVFVTPL TDLRSDFSKF QEMIETTLDM DQVENHEFLV KPSFDPNLSE 480
 LREIMNDLEK KMOSTLISAA RDLGLDPGKQ IKLDSSAQFG YYFRVTCKEE KVLNNKNFS 540
 TVDIQKNGVK FTNSKLTSLN EYTKNKTEY EEAQDAIVKE IVNISSGYVE PMQTLNDVLA 600
 QLDAVVSFAH VSNAPVPYV RPAILEKGQ RIILKASRHA CVEVQDEIAF IPNDVYFEKD 660
 KQMFHITGP NMGGKSTYIR QTVIVLMAQ IGCVPCESA EVSIVDCILA RVGAGDSQLK 720
 45 GVSTFMAEML ETASILRSAT KDSLIIIDEL GRGTSTYDGF GLAWAISEYI ATKIGAFCMF 780
 ATHFHELTAL ANQIPTVNNL HVTALTTEET LTMLYQVKKG VCDQSFGIHV AELANFPKHV 840
 IECAKQKALE LEEFYIGES QGYDIMEPAA KKCYLREQG EKIIQEFLSK VKOMPTEMS 900
 EENITIKLKQ LKAEVIAKNN SFVNEIISRI KVT 934

Human MSH2 cDNA

ggcgggaaac agcttagtggt gtgtgggggc gcgcattttc ttcaaccagg aggtgaggag 60
 gtttcgacat ggcggtgcag ccgaaggaga cgctgcagtt ggagagcgcg gccgaggtcg 120
 gcttcgtgcg cttctttcag ggcatgccgg agaagccgac caccacagtg cgctttttcg 180
 5 accggggcga cttctatacg gcgcacggcg aggaacgcgt gctggccgcc cgggaggtgt 240
 tcaagaccca gggggtgac aagtacatgg ggccggcagg agcaagaat ctgcagagtg 300
 ttgtgcttag taaaatgaat ttgaatctt ttgtaaaaga tcttctctg gttcgtcagt 360
 atagagttga agtttataag aatagagctg gaaataaggc atccaaggag aatgattggt 420
 atttgccata taaggcttct cctggcaatc tctctcagtt tgaagacatt ctctttggt 480
 10 acaatgatat gtcagcttcc attggtgttg tgggtgttaa aatgtccga gttgatggcc 540
 agagacaggt tggagttggg tatgtggatt ccatacagag gaaactagga ctgtgtgaat 600
 tccctgataa tgatcagttc tccaatcttg aggtctctct catccagatt ggaccaaagg 660
 aatgtgtttt acccgaggga gagactgctg gagacatggg gaaactgaga cagataattc 720
 aaagaggagg aattctgac acagaaagaa aaaaagctga cttttccaca aaagacattt 780
 15 atcaggacct caaccggttg ttgaaaggca aaaaaggaga gcagatgaat agtgctgtat 840
 tgccagaaat ggagaatcag gttgcagttt catcactgtc tgcggtaatc aagtttttag 900
 aactcttacc agatgattcc aactttggac agtttgaact gactactttt gacttcagcc 960
 agtatatgaa attggatatt gcagcagtc gagcccttaa cctttttcag gttctgttg 1020
 aagataccac tggctctcag tctctggctg ccttgcgtga taagtgtaaa accctcaa 1080
 20 gacaaagact tgtaaccag tggattaagc agcctctcat ggataagaac agaataagag 1140
 agagattgaa tttagtggaa gctttttag aagatgcaga attgaggcag actttacaag 1200
 aagatttact tegtgcattc ccagacttta accgacttgc caagaagttt caagacaag 1260
 cagcaactt acaagattgt taccgactct atcagggtat aaatcaacta cctaagtta 1320
 tacaggctct ggaaaaacat gaaggaaaac accagaaatt attgttgga gtttttgtga 1380
 25 ctctctttac tgatcttctg tctgacttct ccaagtttca ggaaatgata gaaacaactt 1440
 tagatatgga tcaggtggaa aaccatgaat tcttgtaaa accttcattt gatcctaate 1500
 tcagtgaatt aagagaaata atgaatgact tggaaaagaa gatgcagtc acattaataa 1560
 gtgcagccag agatcttggc ttggaccctg gcaaacagat taaactggat tccagtgcac 1620
 agtttggaata ttactttctg gtaacctgta aggaagaaaa agtcttctg aacaataaaa 1680
 30 acttttagtac tgtagatac cagaagaatg gtgttaaatt taccaacagc aaattgactt 1740
 ctttaaatga agagtatacc aaaaataaaa cagaatatga agaagccag gatgccattg 1800
 ttaaagaaat tgtcaatatt tcttcaggct atgtagaacc aatgcagaca ctcaatgatg 1860
 tgttagctca gctagatgct gttgtcagct ttgctcacgt gtcaaatgga gcacctgtc 1920
 catatgtacg accagccatt ttggagaaag gacaaggaag aattatatta aaagcalcca 1980
 35 ggcatgcttg tgttgaagtt caagatgaaa ttgcatttat tccaatgac gtatactttg 2040
 aaaaagataa acagatgttc cacatcatta ctggcccaa tatgggaggt aaatcaacat 2100
 atattcgaca aactggggtg atagtactca tggcccaa atgggtgttt gtgccatgtg 2160
 agtcagcaga agtgctcatt gtggactgca tcttagcccc agtaggggct ggtgacagtc 2220
 aattgaaagg agtctccacg ttcattggctg aaatgttggg aactgcttct atcctcaggt 2280
 40 ctgcaaccaa agattcatta ataactatag atgaattggg aagaggaact tctacctag 2340
 atggatttgg gttagcatgg gctatatcag aatacattgc aacaaagatt ggtgcttttt 2400
 gcatgtttgc aacctatttt catgaactta ctgccttggc caatcagata ccaactgtta 2460
 ataacttaca tgtcacagca ctaccactg aagagacctt aactatgctt tatcaggtga 2520
 agaaaagggt ctgtgatcaa agttttggga ttcatgttgc agagcttgc aatttcctta 2580
 45 agcatgtaat agagtgtgct aaacagaaa ccttggaaat tgaggagttt cagtatattg 2640
 gagaatcgca aggatgat atcatggaac cagcagcaaa gaagtgtat ctggaagag 2700
 agcaagggtg aaaaattatt caggagtcc tgtccaaggt gaaacaaatg ccttttactg 2760
 aatgtcaga agaaaacatc acaataaagt taaaacagct aaaagctgaa gtaatagcaa 2820
 agaataatag ctttgttaat gaaatcattt caccgaaaa agttactacg tgaaaaatcc 2880

cagtaatgga atgaaggtaa tattgataag ctattgtctg taatagtttt atattgtttt 2940
 atattaaccc tttttccata gtgttaactg tcagtgccca tgggctatca acttaataag 3000
 atatttagta atattttact ttgaggacat tttcaaagat ttttatttg aaaaatgaga 3060
 gctgtaactg aggactgttt gcaattgaca taggcaataa taagtgatgt gctgaatttt 3120
 5 ataaataaaa tcatgtagtt tgtgg
 3145

human MLH1 protein

MSFVAGVIRR LDETUVNRIA AGEVIQRPAN AIKEMIENCL DAKSTSIQVI VKEGGLKLIQ 60
 10 IQDNGTGIRK EDLDIVCERF TTSKLQSFED LASISTYGRF GEALASISHV AHVTITTKTA 120
 DGKCAIRASY SDGKLRKAPPK PCAGNQGTQI TVEDLFYNIA TRRKALKNPS EYGGKILEVV 180
 GRYSVHNAGI SFSVKKQGET VADVRLPNA STVDNIRSIF GNAVSRELIE IGCEDKTLAF 240
 KMNGYISNAN YSVKKCIFLL FINHRLVEST SLRKAIETVY AAYLPKNTHP FLYLSLEISP 300
 QNVDVNVHPT KHEVHFLHEE SILERVQCHI ESKLLGSNS RMYFTQTLPL GLAGPSGEMV 360
 15 KSTTSLTSSS TSGSSDKVYA HQMVRTDSRE QKLDAFLQPL SKPLSSQPQA IVTEDKTDIS 420
 SGRARQQDEE MLELPAPAEV AAKNQSLGEGD TTKGTSEMSE KRGPTSSNPR KRHRSDSVE 480
 MVEDDSRKEM TAACTPRRRI INLTSVLSLO EEINEQGHEV LREMLNHSF VGCVPQWAL 540
 AQHQTKLYLL NTKLSEELF YQILIYDFAN FGVRLSEPA PLFDLAMLAL DSPESGWTEE 600
 DGPKEGLAEY IVEFLKKAE MLADYFSLEI DEEGNLIGLP LLIDNYVPL EGLPIFILRL 660
 20 ATEVNWDEEK ECFESLSKEC AMFYSIRKQY ISEESTLSGQ QSEVPGSIPN SHKWTVEHIV 720
 YKALRSHIP PKHFTEDGNI LQLANLPDLY KVFERC 756

Human MLH1 cDNA

cttgctctt ctggcgccaa aatgtcgttc gtggcagggg ttattcggcg gctggacgag 60
 25 acagtgggga accgcatcgc ggcgggggaa gttatccagc gccagctaa tgctatcaaa 120
 gagatgattg agaactgttt agatgcaaaa tccacaagta ttcaagtgtg tgtaaaagag 180
 ggaggcctga agttgattca gatccaagac aatggcaccg ggatcaggaa agaagatctg 240
 gatattgtat gtgaaagggt cactactagt aaactgcagt cctttgagga tttagccagt 300
 atttctacct atggcttttc aggtgaggct ttggccagca taagccatgt ggctcatgtt 360
 30 actattacaa cgaaaacagc tgatggaaa tggtcataca gagcaagtta ctcatagga 420
 aaactgaaag cccctcctaa accatgtgct ggcaatcaag ggaccagat caggtggag 480
 gacctttttt acaacatagc caccaggaga aaagctttta aaatccaag tgaagaatat 540
 gggaataatt tggaaagttg tggcagggtat tcagtacaca atgcaggcat tagtttctca 600
 gttaaaaaac aaggagagac agtagctgat gttaggacac tacccaatgc ctcaaccgtg 660
 35 gacaatatc gctccatctt tggaaatgct gttagtcgag aactgataga aattggatgt 720
 gaggataaaa ccttagcctt caaatgaat ggttacatat ccaatgcaaa ctactcagt 780
 aagaagtga tcttcttact cttcatcaac catcgtctg tagaatcaac ttccttgaga 840
 aaagccatag aaacagtgt tgcagcctat ttgccccaaa acacacacc attcctgtac 900
 ctcatgttag aaatcagtc ccagaatgtg gatgttaatg tgcacccac aaagcatgaa 960
 40 gttcacttcc tgcacgagga gagcatcctg gagcgggtgc agcagcacat cgagagcaag 1020
 ctctggggt ccaattctc caggatgtac ttcaccaga ctttgcacc aggacttgc 1080
 ggccccctg gggagatggt taaatccaca acaagtctga cctcgtctc tacttctgga 1140
 agtagtgata aggtctatgc ccaccagatg gtctgtacag attcccggga acagaagctt 1200
 gatgcatttc tgcagcctc gagcaaaccc ctgtccagtc agccccaggc cattgtcaca 1260
 45 gaggataaga cagatatctc tagtggcagg gctaggcagc aagatgagga gatgcttgaa 1320
 ctcccagccc ctgctgaagt ggctgcaaaa aatcagagct tggaggggga tacaacaaag 1380
 gggacttcag aaatgtcaga gaagagagga cctacttcca gcaacccag aaagagacat 1440
 cgggaagatt ctgatgtgga aatggtggaa gatgattccc gaaaggaaat gactgcagct 1500
 tgtaccccc ggagaaggat cattaacctc actagtgtt tgagtctcca ggaagaaatt 1560

5 aatgagcagg gacatgaggt tctccgggag atgttgcata accactcctt cgtgggctgt 1620
 gtgaatcctc agtgggcctt ggcacagcat caaaccaagt tataccttct caacaccacc 1680
 aagcttagtg aagaactgtt ctaccagata ctcatattatg attttgccaa ttttggtgtt 1740
 ctcaggttat cggagccagc accgctcttt gaccttgcca tgcttgctt agatagtcca 1800
 10 gagagtggct ggacagagga agatgggtccc aaagaaggac ttgctgaata cattgttgag 1860
 tttctgaaga agaagctga gatgcttgca gactatttct ctttggaat tgatgaggaa 1920
 gggaacctga ttggattacc cttctgatt gacaactatg tgccccctt ggagggactg 1980
 cctatcttca ttcttcgact agccactgag gtgaattggg acgaagaaaa ggaatgtttt 2040
 gaaagcctca gtaagaatg cgtatgttc tattccatcc ggaagcagta catatctgag 2100
 15 gagtcgaccc tctcaggcca gcagagtga gtgcctggct ccattccaaa ctctggaag 2160
 tggactgtgg aacacattgt ctataaagcc ttgcgctcac acattctgcc tctaaacat 2220
 ttcacagaag atggaaatat cctgcagctt gctaacctgc ctgatctata caaagtcttt 2280
 gagaggtgtt aaatatggtt atttatgcac tgtgggatgt gttcttcttt ctctgtattc 2340
 cgatacaaa tggtgtatca aagtgtgata tacaagtgt accaacataa gtgttggtag 2400
 20 cacttaagac ttatactgc cttctgatag tattccttta tacacagtgg attgattata 2460
 aataaataga tgtgtcttaa cata 2484

hPMS2-134 protein
 20 MKQLPAATVR LLSSSQIITS VSVVKELIE NSLDAGATSV DVKLENYGFD KIEVRDNNEG 60
 IKAVDAPVMA MKYITSKINS HEDLENLTTY GFRGEALGSI CCIAEVLITT RTAADNFSTQ 120
 YVLDGSGHIL SQK 133

hPMS2-134 cDNA
 25 cgaggcggat cgggtgttgc atccatggag cgagctgaga gctcgagtac agaacctgct 60
 aaggccatca aacctattga tcggaagta gtccatcaga ttgctcttg gcagggtgta 120
 ctgagcttaa gcactgcgtt aaaggagta gtagaaaaca gtctggatgc tggtgccact 180
 aatattgatc taaagcttaa ggactatgga gtggatctta ttgaagttc agacaatgga 240
 tgtgtggtag aagaagaaaa cttcgaagcc ttaactctga aacatcacac atctaagatt 300
 30 caagagtttg ccgacctaac tcaggttgaa acttttggct ttggggggga agctctgagc 360
 tcactttgtg cactgagcga tgcaccatt tctacctgcc acgcatcgcc gaaggttgga 420
 acttga 426

hMSH6 (human cDNA) ACCESSION U28946
 35 MSRQSTLYSFFPKSPALSDANKASARASREGGAAAAFGASPS
 GGDAWSEAGPGPRPLARSASPPKAKNLNGGLRRSVAPAAPTSCDFSPGDLVWAKMEG
 40 YPWWPCLVYNHPDGTFFIREKGKSVRVHVQFFDDSPTRGWVSKRLLKPYTGSKSKEAQ
 KGGHFYSAPKPEILRAMQRADEALNKDKIKRLELAVCDEPSEPEEEEENEVGTTIYVTDK
 SEEDNEIESEEEVQPKTQGSRRSRQIKRRVISDSSESDIGGSDVEFKPDTKEEGSSD
 45 EISSGVGDSESEGLNSPVKVARKKRMVTNGSLKRKSSRKETPSATKQATSISSEK
 NTLRAFSAPQNSESAHVSGGDDSSRPTVMYHETLEWLKEEKRRDEHRRPDHPDFD
 50 ASTLYVPEDFLNSCTPGMRKWWQIKSQNFDLVICYKVGKFYELHMDALIGVSELGLV
 FMKGNWAHSGFPEIAFGRYSDSLVQKGYKVARVEQTETPEMMEARCRKMAHISKYDRV
 VRREICRIITKGTQTSVLEGDPSSENYSKYLLSLKEKEEDSSGHTRAYGVCVDTSLG
 55 KFFIGQFSDDRHCSRFRITLVANYPVQVLFKGNLSKETKTIKSSLSCSLQEGLI
 SQFWDASKTLRTLLLEEYFREKLSDGIGVMLPQVLKGMTSESDSIGLTPGEKSELALS
 60 ALGGCVFYLKKCLIDQELLSMANFEYIPLSDTVSTTRSGAIFTKAYQRMVLDVTL
 NNLEIFLNGTNGSTEGTLLERVDTCHTPFGKRLKQWLCAPLCNHYAINDRLDAIEDL

MVVPDKISEVVELLKKLPDLERLLSKIHNVGSPLKSNHPDSRAIMYEETYSKKKII
 5 DFLSALEGFKVMCKIIGIMEEVADGFKSKILKQVISLQTKNPEGRFPDLTVELNRWDT
 AFDHEKARKTGLITPKAGFDSDDYQALADIRENEQSLEYLEKQRNRIGCRTIVYWG
 GRNRYQLEIPENFTTRNLPEEYELKSTKKGCKRYWTKTIEKKLANLINAEEERDVS
 10 DCMRRLFYNFDKNYKDWQSAVECIAVLVDLLCLANYSRGGDGPMPRPVILLPEDTPPF
 LELKGSRRHPCITKTFFGDDFI PNDILIGCEEEQENGKAYCVLVTGPNMGGKSTLMRQ
 15 AGLLAVMAQMGCVYPAEVCRLTPIDRVFTRLGASDRIMSGESTFFVELSETASILMHA
 TAHSVLVLDELGRGTATFDGTAIANAVVKELAETIKCRTLFSTHYHSLVEDYSQNVAV
 20 RLGHMACMVENECEPSQETITFLYKFIKACPKSYGFNAARLANLPEEVIQKGRKA
 REFEMNQSLRLFREVLASERSTVDAEAVHKLLTLIKEL"

hPMSR2 (human cDNA) ACCESSION U38964

25 1 ggcgctccta cctgcaagt gctagtgcga agtgctgggc cgcgcctcct gccgtgcatg
 61 ttggggagcc agtacatgca ggtgggctcc acacggagag gggcgagac ccggtgacag
 121 ggctttacct ggtacatcgg catggcgcaa ccaaagcaag agagggtggc gcgtgccaga
 181 caccaacggc cggaaccgc cagacaccaa cggtcggaaa ccgccaagac accaacgctc
 241 ggaaccgccc agacaccaac gctcggaaac cgccagacac caaggctcgg aatccacgce
 30 301 aggccacgac ggaggcgac tacctccctt ctgacctgc tgcctggcgtt cggaaaaaac
 361 gcagtcgggt gtgctctgat tggccaggc tctttgacgt caccgactcg acctttgaca
 421 gagccactag gcgaaaagga gagacgggaa gtatttttcc cgcgccgccc ggaaggggtg
 481 gagcacaacg tcgaaaagcag ccgttgggag cccaggaggc gggcgccctg tgggagccgt
 541 ggagggaact ttccagtcac ccgaggcgga tccggtgttg catccttggg gcgagctgag
 35 601 aactcgagta cagaacctgc taaggccatc aaacctattg atcggaagtc agtccatcag
 661 atttgctctg ggcgggtggt accgagtcta aggccgaatg cgggtgaagga gttagtagaa
 721 aacagctcgg atgctggtgc cactaatgtt gatctaaagc ttaaggacta tggagtggat
 781 ctcatggaag ttccaggcaa tggatgtggg gtagaagaag aaaacttcga aggcctttact
 841 ctgaaacatc acacatgtaa gattcaagag ttgcccagc taactcaggt ggaactttt
 40 901 ggctttcggg gggaagctct gagctcactt tgtgactga gtgatgtcac catttctacc
 961 tgccgtgtat cagcgaaggt tgggactcga ctggtgtttg atcactatgg gaaaatcatc
 1021 cagaaaaccc cctacccccc cccagagggt atgacagtca gcgtgaagca gttattttct
 1081 acgctacctg tgcaccataa agaatttcaa aggaatatta agaagaaacg tgcctgtctc
 1141 ccccttcgct tctgccgtga ttgtcagttt cctgaggcct cccagccat gcttctgta
 45 1201 cagcctgtag aactgactcc tagaagtacc ccacccacc cctgctcctt ggaggacaac
 1261 gtgatcactg tattcagctc tgtcaagaat ggtccaggtt cttctagatg atctgcacaa
 1321 atgggttctc tctccttccc tgatgtctgc cattagcatt ggaataaagt tcctgctgaa
 1381 aatccaaaaa aaaaaaaaaa aaaaaaaa

50 hPMSR2 (human protein) ACCESSION U38964
 MAQPKQERVARARHORSETARHORSETAKTPTLGNRQTPTLGNR

55 QTPRLGIHARPRRATSLTLTLLAFGKNVRCALIGPSLTSRTRPLTEPLGEKERR
 EVFFPPRPERVEHNVESSRWEPRRRGACGSRGGNFSPRGSGVASLERAENSSTPEA
 60 KAIPIDRKSVDHQCISGPPVPSLRPNAVKELVENS LDAGATNVDLKLKDYGVDLIEVS
 GNGCGVEEENFEGFTLKHHTCKIQEFADLTQVETFGFRGEALSSLCALSDVTISTCRV
 SAKVGTRLVFDHYGKIIQKTPYPRPRGMTVSVKQLFSTLPVHHKEFQRNIKKKRACFP
 65 FAFCRDCQFPEASPAMLPVQPVELTPRSTPPHPCSLEDNVITVFSSVKNGPGSSR

HPMSR3 (human cDNA) ACCESSION U38979

70 1 tttttagaaa ctgatgttta ttttccatca accatttttc catgctgctt aagagaatat
 61 gcaagaacag cttaaagacca gtcagtgggt gctcctaccc attcagtggtc ctgagcagtg
 121 gggagctgca gaccagtctt ccgtggcagg ctgagcgctc cagtcttcag tagggaattg
 181 ctgaataggg acagagggca cctgtacacc ttcagaccag tctgcaacct caggctgagt
 241 agcagtgaac tcaggagcgg gagcagtcca ttcaccctga aattcctcct tggctactgc
 301 cttctcagca gcagcctgct cttctttttc aatctcttca ggatctctgt agaagtacag
 75 361 atcaggcatg acctcccatg ggtgttcacg ggaatgggtg ccacgcagtc gcagaacttc
 421 ccgagccagc atccaccaca ttaaacccac tgagtgaact ccctgtgtgt tgcattggat
 481 ggcaatgtcc acatagcgca gaggagaatc tgtgttacac agcgcaatgg taggtaggtt

541 aacataagat gcctccgtga gaggcgaagg ggcggcggga cccgggcctg gcccgatatg
601 gtccttgagg gcctagacta ggcctgcgct gtatggtgag cccagggag gcggatctgg
661 gccccagaa ggacacccgc ctggatttgc cccgtagccc ggcggggcc cctcgggagc
721 agaacagcct tggtaggtg gacaggagg gacctcgcga gcagacggc gcgcagcga
781 cagcagcccc gccccggcct ctcgggagcc ggggggcaga ggctgcggag cccagggagg
841 gtctatcagc cacagtctct gcatgtttcc aagagcaaca ggaatgaac acattgcagg
901 ggcagatgtc attcaaaagt gtggctgtgg atttcaccca ggaggagtgg cggcaactgg
961 accctgatga gaagatagca tacggggatg tgatgttga gaactacagc catctagttt
1021 ctgtggggtg tgattatcac caagccaaac atcatcatgg agtggagggtg aaggaagtgg
1081 agcaggggaga ggagccgtgg ataattggaag gtgaatttcc atgtcaacat agtccagaac
1141 ctgctaaggc catcaaacct attgatcggg agtcagtcga tcagatttgc tctgggcccag
1201 tggtagctgag tctaaagcct gcagtgaagg agttagtaga aaacagtcct gatgctgggtg
1261 ccactaatat tgatctaaag cttaaggact atggagtggg tctcattgaa gtttcagaca
1321 atggatgtgg ggtagaagaa gaaaactttg aaggcttaac ctctttcagc tctgaaacat
1381 cacacatgta agattcaaga gtttgccgac ctaactgaag ttgaaacttt cggttttcag
1441 ggggaagctc tgagctcact gtgtgcactg agcgatgtca ccatttctac ctgccacggc
1501 ttggtgaagg ttgggactcg actggtgttt gatcacgatg ggaaatcat ccaggaaacc
1561 ccttaccccc accccagagg gaccacagtc agcgtgaagc agttatttcc tacgctacct
1621 gtgcgcata aggaatttca aaggaaattt aagaagacgt gcctgcttcc ccttcgcctt
1681 ctgccgtgat tgcagtttc ctgaggcctc cccagccatg cttctgtac agcctgcaga
1741 actgtgagtc aattaaacct cttttcttca taaattaaaa aaaaa

25 hPMSR3 (human protein) ACCESSION U38979

MCPWRPRLGRRCMVSPREADLGPQKDLRLDLPRSPARAPREQNS

30 LGEVDRRGPREQTRAPATAAPRPLGSRGAEEAEFQEGLSATVSACFQEQQEMNTLQG

PVSFKDVAVDFTQEEWRQLDPDEKIAYGDMLENYSHLVSVGYDYHQAKHHHGVEVKE

VEQGEPPWIMEGEFPCQHSPEPAKAIKPIDRKSVHQICSGPVVLSLSTAVKELVENS

35 DAGATNIDLKLDYGVDLIEVSDNGCGVEEENFEGLISFSSETSHM"

hPMSL9 (human cDNA) ACCESSION NM_005395

40 1 atgtgtcctt ggcggcctag actaggccgt cgctgtatgg tgagcccccag ggaggcggat
61 ctggggcccc agaaggacac ccgcctggat ttgccccgta gcccggcccg ggcctctcgg
121 gagcagaaca gccttggtga ggtggacagg aggggacctc gcgagcagac gcgcgcgcca
181 gcgacagcag ccccgccccg gcctctcggg agccgggggg cagaggctgc ggagccccag
241 gagggtctat cagccacagt ctctgcatgt ttccaagagc aacaggaaat gaacacattg
45 301 caggggccag tgcattcaa agatgtggct gtggatttca cccaggagga gtggcgcaa
361 ctggaccctg atgagaagat agcatacggg gatgtgatgt tggagaacta cagccatcta
421 gtttctgtgg ggtatgatta tcaccaagcc aaacatcatc atggagtggg ggtgaaggaa
481 gtggagcagg gagaggagcc gtggataatg gaaggtgaat ttccatgtca acatagcca
541 gaacctgcta aggccatcaa acctattgat cggaagtcag tccatcagat ttgctctggg
50 601 ccagtggtac tgagtctaag cactgcagtg aaggagttag tagaaaacag tctggatgct
661 ggtgccacta atattgatct aaagcttaag gactatggag tggatctcat tgaagtttca
721 gacaatggat gtggggtaga agaagaaaac tttgaaggct taatctcttt cagctctgaa
781 acatcacaca tgtaa

55 hPMSL9 (human protein) ACCESSION NM_005395

MCPWRPRLGRRCMVSPREADLGPQKDLRLDLPRSPARAPREQNS

60 LGEVDRRGPREQTRAPATAAPRPLGSRGAEEAEFQEGLSATVSACFQEQQEMNTLQG

PVSFKDVAVDFTQEEWRQLDPDEKIAYGDMLENYSHLVSVGYDYHQAKHHHGVEVKE

65 VEQGEPPWIMEGEFPCQHSPEPAKAIKPIDRKSVHQICSGPVVLSLSTAVKELVENS

DAGATNIDLKLDYGVDLIEVSDNGCGVEEENFEGLISFSSETSHM"

References

1. Attfield, P.V. and Pinney, R.J. 1985. Elimination of multicopy plasmid R6K by bleomycin. *Antimicrob. Agents Chemother.* 27(6):985-988.
- 5 2. Baker S.M., Bronner, C.E., Zhang, L., Plug, A.W., Robatez, M., Warren, G., Elliott, E.A., Yu, J., Ashley, T., Arnheim, N., Bradley, N., Flavell, R.A., and Liskay, R.M. 1995. Male defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. *Cell* 82:309-319.
- 10 3. Berry, A. 1996. Improving production of aromatic compounds in *Escherichia coli* by metabolic engineering. *Trends Biotechnol.* 14(7):250-256.
- 15 4. Bronner, C.E., Baker, S.M., Morrison, P.T., Warren, G., Smith, L.G., Lescoe, M.K., Kane, M., Earabino, C., Lipford, J., Lindblom, A., Tannergard, P., Bollag, R.J., Godwin, A., R., Ward, D.C., Nordenskjold, M., Fishel, R., Kolodner, R., and Liskay, R.M. 1994. Mutation in the DNA mismatch repair gene homologue *hMLH1* is associated with hereditary
- 20 non-polyposis colon cancer. *Nature* 368:258-261.
5. de Wind N., Dekker, M., Berns, A., Radman, M., and Riele, H.T. 1995. Inactivation of the mouse *Msh2* gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer.
- 25 *Cell* 82:321-300.
6. Drummond, J.T., Li, G.M., Longley, M.J., and Modrich, P. 1995. Isolation of an hMSH2-p160 heterodimer that restores mismatch repair to tumor cells. *Science* 268:1909-1912.

30

7. Drummond, J.T., Anthoney, A., Brown, R., and Modrich, P. 1996. Cisplatin and adriamycin resistance are associated with MutLa and mismatch repair deficiency in an ovarian tumor cell line. *J.Biol.Chem.* 271:9645-19648.
8. Edelmann, W., Cohen, P.E., Kane, M., Lau, K., Morrow, B., Bennett, S., Umar, A., Kunkel, T., Cattoretti, G., Chagnatti, R., Pollard, J.W., Kolodner, R.D., and Kucherlapati, R. 1996. Meiotic pachytene arrest in MLH1-deficient mice. *Cell* 85:1125-1134.
9. Fishel, R., Lescoe, M., Rao, M.R.S., Copeland, N.J., Jenkins, N.A., Garber, J., Kane, M., and Kolodner, R. 1993. The human mutator gene homolog *MSH2* and its association with hereditary nonpolyposis colon cancer. *Cell* 7:1027-1038.
10. Fu, K.P., Grace, M.E., Hsiao, C.L., and Hung, P.P. 1988. Elinination of antibiotic-resistant plasmids by quinolone antibiotics. *Chemotherapy* 34(5):415-418.
11. Leach, F.S., Nicolaides, N.C, Papadopoulos, N., Liu, B., Jen, J., Parsons, R., Peltomaki, P., Sistonen, P., Aaltonen, L.A., Nystrom-Lahti, M., Guan, X.Y., Zhang, J., Meltzer, P.S., Yu, J.W., Kao, F.T., Chen, D.J., Cerosaletti, K.M., Fournier, R.E.K., Todd, S., Lewis, T., Leach R.J., Naylor, S.L., Weissenbach, J., Mecklin, J.P., Jarvinen, J.A., Petersen, G.M., Hamilton, S.R., Green, J., Jass, J., Watson, P., Lynch, H.T., Trent, J.M., de la Chapelle, A., Kinzler, K.W., and Vogelstein, B. 1993. Mutations of a *mutS* homolog in hereditary non-polyposis colorectal cancer. *Cell* 75:1215-1225.

12. Li, G.-M., and Modrich, P. 1995. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human mutL homologs. *Proc. Natl. Acad. Sci. USA* **92**:1950-1954.
- 5
13. Liu, B., Parsons, R., Papadopoulos, N., Nicolaides, N.C., Lynch, H.T., Watson, P., Jass, J.R., Dunlop, M., Wyllie, A., Peltomaki, P., de la Chapelle, A., Hamilton, S.R., Vogelstein, B., and Kinzler, K.W. 1996. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. *Nat. Med.* **2**:169-174.
- 10
14. Modrich, P. 1994. Mismatch repair, genetic stability, and cancer. *Science* **266**:1959-1960.
- 15
15. Nicolaides, N.C., Gualdi, R., Casadevall, C., Manzella, L., and Calabretta, B. 1991. Positive autoregulation of *c-myb* expression via MYB binding in the 5' flanking region of the human *c-myb* gene. *Mol. Cell. Biol.* **11**:6166-6176.
- 20
16. Nicolaides, N.C., Correa, I., Casadevall, C., Travali, S., Soprano, K.J., and Calabretta, B. 1992. The Jun family members, c-JUN and JUND, transactivate the human *c-myb* promoter via an Ap1 like element. *J. Biol. Chem.* **267**, 19665-19672.
- 25
17. Nicolaides, N.C., Papadopoulos, N., Liu, B., Wei, Y.F., Carter, K.C., Ruben, S.M., Rosen, C.A., Haseltine, W.A., Fleischmann, R.D., Fraser, C.M., Adams, M.D., Venter, C.J., Dunlop, M.G., Hamilton, S.R., Petersen, G.M., de la Chapelle, A., Vogelstein, B., and kinzler, K.W. 1994. Mutations of two PMS homologs in hereditary nonpolyposis colon cancer. *Nature* **371**: 75-80.
- 30

18. Nicolaides N.C., Kinzler, K.W., and Vogelstein, B. 1995. Analysis of the 5' region of PMS2 reveals heterogenous transcripts and a novel overlapping gene. *Genomics* 29:329-334.
- 5
19. Nicolaides, N.C., Carter, K.C., Shell, B.K., Papadopoulos, N., Vogelstein, B., and Kinzler, K.W. 1995. Genomic organization of the human PMS2 gene family. *Genomics* 30:195-206.
- 10
20. Nicolaides, N.C., Palombo, F., Kinzler, K.W., Vogelstein, B., and Jiricny, J. 1996. Molecular cloning of the N-terminus of GTBP. *Genomics* 31:395-397.
21. Palombo, F., Hughes, M., Jiricny, J., Truong, O., Hsuan, J. 1994.
- 15
- Mismatch repair and cancer. *Nature* 36:417.
22. Palombo, F., Gallinari, P., Iaccarino, I., Lettieri, T., Hughes, M.A., Truong, O., Hsuan, J.J., and Jiricny, J. 1995. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. *Science*
- 20
- 268:1912-1914.
23. Pang, Q., Prolla, T.A., and Liskay, R.M. 1997. Functional domains of the *Saccharomyces cerevisiae* Mlh1p and Pms1p DNA mismatch repair proteins and their relevance to human hereditary nonpolyposis colorectal
- 25
- cancer-associated mutations. *Mol. Cell. Biol.* 17:4465-4473.
24. Papadopoulos, N., Nicolaides, N.C., Wei, Y.F., Carter, K.C., Ruben, S.M., Rosen, C.A., Haseltine, W.A., Fleischmann, R.D., Fraser, C.M., Adams, M.D., Venter, C.J., Dunlop, M.G., Hamilton, S.R., Petersen, G.M.,
- 30
- de la Chapelle, A., Vogelstein, B., and kinzler, K.W. 1994. Mutation of a

- mutL homolog is associated with hereditary colon cancer. *Science* **263**:1625-1629.
25. Parsons, R., Li, G.M., Longley, M.J., Fang, W.H., Papadopolous, N.,
5 Jen, J., de la Chapelle, A., Kinzler, K.W., Vogelstein, B., and Modrich, P.
1993. Hypermutable and mismatch repair deficiency in RER⁺ tumor
cells. *Cell* **75**:1227-1236.
26. Parsons, R., Li, G.M., Longley, M., Modrich, P., Liu, B., Berk, T.,
10 Hamilton, S.R., Kinzler, K.W., and Vogelstein, B. 1995. Mismatch repair
deficiency in phenotypically normal human cells. *Science* **268**:738-740.
27. Perucho, M. 1996. Cancer of the microsatellite mutator phenotype.
Biol Chem. **377**:675-684.
- 15 28. Prolla, T.A., Pang, Q., Alani, E., Kolodner, R.A., and Liskay, R.M.
1994. MLH1, PMS1, and MSH2 Interaction during the initiation of DNA
mismatch repair in yeast. *Science* **264**:1091-1093.
- 20 29. Strand, M., Prolla, T.A., Liskay, R.M., and Petes, T.D. Destabilization
of tracts of simple repetitive DNA in yeast by mutations affecting DNA
mismatch repair. 1993. *Nature* **365**:274-276.
- 25 30. Studier, F.W. Use of bacteriophage T7 lysozyme to improve an
inducible T7 expression system. 1991. *J. Mol. Biol.* **219**(1):37-44.
31. Su, S.S., Lahue, R.S., Au, K.G., and Modrich, P. 1988. Mismatch
specificity of methyl directed DNA mismatch corrections in vitro. *J. Biol.*
Chem. **263**:6829-6835.

32. Nicolaides NC, Littman SJ, Modrich P, Kinzler KW, Vogelstein B 1998. A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. *Mol Cell Biol* **18**:1635-1641.
- 5 33. Aronshtam A, Marinus MG. 1996. Dominant negative mutator mutations in the mutL gene of *Escherichia coli*. *Nucleic Acids Res* **24**:2498-2504.
- 10 34. Wu TH, Marinus MG. 1994. Dominant negative mutator mutations in the mutS gene of *Escherichia coli*. *J Bacteriol* **176**:5393-400.
35. Brosh RM Jr, Matson SW. 1995. Mutations in motif II of *Escherichia coli* DNA helicase II render the enzyme nonfunctional in both mismatch repair and excision repair with differential effects on the unwinding reaction. *J Bacteriol* **177**:5612-5621.
- 15 36. Studamire B, Quach T, Alani, E. 1998. *Saccharomyces cerevisiae* Msh2p and Msh6p ATPase activities are both required during mismatch repair. *Mol Cell Biol* **18**:7590-7601.
- 20 37. Alani E, Sokolsky T, Studamire B, Miret JJ, Lahue RS. 1997. Genetic and biochemical analysis of Msh2p-Msh6p: role of ATP hydrolysis and Msh2p-Msh6p subunit interactions in mismatch base pair recognition. *Mol Cell Biol* **17**:2436-2447.
- 25 38. Lipkin SM, Wang V, Jacoby R, Banerjee-Basu S, Baxevanis AD, Lynch HT, Elliott RM, and Collins FS. 2000. MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. *Nat Genet* **24**:27-35.
- 30 39. Lee CC, Lin HK, Lin JK. 1994. A reverse mutagenicity assay for alkylating agents based on a point mutation in the beta-lactamase gene at the active site serine codon. *Mutagenesis* **9**:401-405.
- 35 40. Vidal A, Abril N, Pueyo C. 1995. DNA repair by Ogt alkyltransferase influences EMS mutational specificity. *Carcinogenesis* **16**:817-821.
41. Fu, K.P., Grace, M.E., Hsiao, C.L., and Hung, P.P. 1988. Elimination of antibiotic-resistant plasmids by quinolone antibiotics. *Chem. Abstracts* **34**(5):415-418.
- 40 42. BiWang, H., ZhiPeng, H., and Xiong, G. 1999. Transformation of *Escherichia coli* and *Bacillus thuringiensis* and their plasmid curing by

electroporation. J. of Fujian Agricultural University 28(1):43-46.

43. Brosius, J. 1988. Expression vectors employing lambda-, trp-, lac-,
5 and lpp-derived promoters. Biotechnology 10:205-225.

WE CLAIM:

1. A method for making a hypermutable bacteria, comprising the step of:
introducing into a bacterium a polynucleotide comprising a dominant
5 negative allele of a mismatch repair gene under the control of an inducible
transcription regulatory sequence, whereby the cell becomes inducibly
hypermutable.
2. The method of claim 1 wherein the mismatch repair gene is MutH from
any species.
- 10 3. The method of claim 1 wherein the mismatch repair gene is a MutS
homolog from any species.
4. The method of claim 1 wherein the mismatch repair gene is a MutL
homolog from any species.
5. The method of claim 1 wherein the mismatch repair gene is a MutY
15 homolog from any species.
6. The method of claim 1 wherein the mismatch repair gene is *PMS2*.
7. The method of claim 1 wherein the mismatch repair gene is plant *PMS2*.
8. The method of claim 1 wherein the mismatch repair gene is *MLH1*.
9. The method of claim 1 wherein the mismatch repair gene is *MLH3*.
- 20 10. The method of claim 1 wherein the mismatch repair gene is *MSH2*.
11. The method of claim 1 wherein the mismatch repair gene is a *PMSR* or
PMSL homolog.
12. The method of claim 3 wherein the allele comprises a truncation
mutation.
- 25 13. The method of claim 4 where the allele comprises a truncation
mutation.
14. The method of claim 6 where the allele comprises a truncation
mutation.
15. The method of claim 7 where the allele comprises a truncation
30 mutation.

16. The method of claim 4 wherein the allele comprises a truncation mutation at codon 134.
17. The method of claim 6 wherein the allele comprises a truncation mutation at codon 134.
- 5 18. A homogeneous composition of cultured, hypermutable, bacteria which comprise a dominant negative allele of a mismatch repair gene under the control of an inducible transcriptional regulatory sequence.
19. The homogeneous composition of claim 18 wherein the mismatch repair gene is a *mutL* gene or a homolog thereof.
- 10 20. The homogeneous composition of claim 18 wherein the mismatch repair gene is *PMS2* or a homolog thereof.
21. The homogeneous composition of claim 18 wherein the mismatch repair gene is *MLH1* or a homolog thereof.
22. The homogeneous composition of claim 18 wherein the mismatch
- 15 repair gene is *PMSR* or a *PMSR* homolog.
23. The homogeneous composition of claim 18 wherein the mismatch repair gene is *mutS* or a homolog thereof.
24. The homogeneous composition of claim 18 wherein the mismatch repair gene is eukaryotic.
- 20 25. The homogeneous composition of claim 18 wherein the mismatch repair gene is prokaryotic.
26. The homogeneous composition of claim 20 wherein the bacteria comprise a protein which consists of the first 133 amino acids of *PMS2*.
27. The homogeneous composition of claim 26 wherein the protein is
- 25 human *PMS2*.
28. The homogeneous composition of claim 23 comprising a mammalian *MutS* protein.
29. The homogeneous composition of claim 19 comprising a mammalian *MutL* protein.

30

30. The homogeneous composition of claim 19 comprising a eukaryotic MutL protein.
31. The homogeneous composition of claim 23 comprising a protein which
5 consists of a eucaryotic MutS protein.
32. A method for generating a mutation in a gene of interest comprising the steps of:
- growing a bacterial culture comprising the gene of interest and a dominant negative allele of a mismatch repair gene under the control of an
10 inducible transcriptional regulatory sequence, wherein the cell is hypermutable;
- testing the cell to determine whether the gene of interest harbors a mutation.
33. The method of claim 32 wherein the step of testing comprises
15 analyzing a nucleotide sequence of the gene of interest.
34. The method of claim 32 wherein the step of testing comprises analyzing mRNA transcribed from the gene of interest.
35. The method of claim 32 wherein the step of testing comprises analyzing a protein encoded by the gene of interest.
- 20 36. The method of claim 32 wherein the step of testing comprises analyzing a phenotype associated with the gene of interest.
37. The method of claim 32 wherein bacteria in the bacterial culture are made by the process of introducing a polynucleotide comprising a dominant negative allele of a mismatch repair gene into a bacterium, whereby the cell
25 becomes hypermutable.
38. The method of claim 37 wherein the step of testing comprises analyzing the nucleotide sequence from the gene of interest.
39. The method of claim 37 wherein the step of testing comprises analyzing a protein encoded by the gene of interest.

40. The method of claim 37 wherein the step of testing comprises analyzing a phenotype associated with the gene of interest.
41. A method for generating a mutation in a gene of interest comprising the steps of:
- 5 growing a bacterium comprising the gene of interest and a dominant negative allele of a mismatch repair gene under the transcriptional control of an inducible regulatory sequence to form a population of mutated bacteria;
- cultivating the population of mutated bacteria under trait selection
- 10 conditions; and
- testing at least one of the cultivated bacteria to determine whether the gene of interest harbors a mutation.
42. The method of claim 41 wherein the step of testing comprises analyzing a nucleotide sequence of the gene of interest.
- 15 43. The method of claim 41 wherein the step of testing comprises analyzing mRNA transcribed from the gene of interest.
44. The method of claim 41 wherein the step of testing comprises analyzing a protein encoded by the gene of interest.
45. The method of claim 41 wherein the step of testing comprises
- 20 analyzing a phenotype associated with the gene of interest.
46. The method of claim 41 further comprising the step of growing a cultivated bacteria harboring a mutation in the gene of interest to manufacture a protein produced by said bacteria and harvesting the protein therefrom.
- 25 47. The method of claim 41 further comprising the step of growing a cultivated bacteria harboring a mutation in the gene of interest to biotransform a substrate.
48. The method of claim 41 further comprising the step of growing a cultivated bacteria harboring a mutation in the gene of interest to
- 30 bioremediate.

49. The method of claim 41 wherein the gene of interest is an antibiotic resistance determinant and further comprising the step of comparing the genome of the cultivated bacteria harboring a mutation in the antibiotic resistance determinant to a genome of a corresponding wild type strain, thereby identifying the gene of interest.
50. The method of claim 41 further comprising the step of growing a cultivated bacteria harboring a mutation in the gene of interest to screen effects of a compound library.
51. A method for enhancing the mutation rate of a bacterium, comprising the steps of:
- exposing a bacterium comprising a dominant negative allele of an MMR gene to a mutagen whereby the mutation rate of the bacterium is enhanced in excess of the rate in the absence of mutagen and in excess of the rate in the absence of the dominant negative allele.
52. The method of claim 51 wherein the mutagen is a chemical mutagenic agent.
53. The method of claim 51 wherein the mutagen is a DNA alkylating agent.
54. The method of claim 51 wherein the mutagen is a DNA intercalating agent.
55. The method of claim 51 wherein the mutagen is a DNA oxidizing agent.
56. The method of claim 51 wherein the mutagen is ionizing radiation.
57. The method of claim 51 wherein the chemical mutagen is ultraviolet radiation.
58. A method for generating an MMR-proficient bacterium with a new output trait, comprising:
- growing a mismatch repair deficient bacterium comprising a defective mismatch repair gene allele and a gene of interest, to form a population of mutated bacteria;

cultivating the population of mutated bacteria under trait selection conditions;

testing at least one of the cultivated bacteria to determine that the gene of interest harbors a mutation; and

5 restoring mismatch repair activity to the at least one cultivated bacteria.

59. The method of claim 58 wherein the mismatch repair deficient bacterium comprises a dominant negative allele of a mismatch repair gene.

60. The method of claim 59 where in the step of restoring MMR activity
10 comprises removing an inducer chemical that positively regulates the dominant negative MMR allele's expression.

61. The method of claim 59 where in the step of restoring MMR activity comprises excising the dominant negative gene by recombination.

62. The method of claim 59 where in the step of restoring MMR activity
15 comprises knocking out the MMR dominant negative gene allele.

63. The method of claim 59 where in the step of restoring MMR activity comprises negatively selecting for loss of the dominant negative allele from bacterial host.

64. The method of claim 58 wherein the mismatch repair deficient
20 bacterium is treated with a mutagen to enhance the rate of mutation.

65. The method of claim 58 wherein the mismatch repair deficient bacterium is treated with a chemical mutagen to enhance the rate of mutation.

66. The method of claim 58 wherein the mismatch repair deficient
25 bacterium is treated with ionizing radiation to enhance the rate of mutation.

67. The method of claim 58 wherein the mismatch repair deficient bacterium is treated with ultraviolet (UV) irradiation to enhance the rate of mutation.

68. The method of claim 58 wherein the step of restoring MMR activity comprises complementing with a wild-type MMR allele.
69. The method of claim 51 wherein the dominant negative allele is under the control of an inducible promoter.
- 5 70. The method of claim 58 wherein the dominant negative allele is under the control of an inducible promoter.




FIGURE 1.

Western blot analysis of IPTG-induced DH10B bacteria expressing the empty vector (lane 1) or hPMS134 dominant negative gene (lane 2). Lysates from bacteria were loaded onto SDS-PAGE gels and probed with an antibody against the human PMS2 N-terminus.




Figure 2.
Western blot of PMS134V5 and PMSR3V5 in IPTG-treated (+) and untreated (-) samples in BL21 bacteria.
Blots were probed with an anti-V5 antibody which is directed to the C-terminal tag of each protein.

PMS134 Expressing bacteria produce KAN^r phenotype




Figure 3. Number of Kanamycin Resistant PMS134 and vector control DH10B clones. IPTG-induced strains were grown and plated onto AMP and KAN plates and grown for an additional 18 hours at 37°C to identify number of KAN resistant clones due to genetic alteration.

PMS134 and PMSR3 expressing bacteria produce KAN^r phenotype




Figure 4. Number of Kanamycin resistant PMS134, PMSR3 and vector control BL21 clones. IPTG-induced strains were grown and plated onto KAN plates and grown for 18 hours at 37°C to identify number of KAN resistant clones due to genetic alteration.




Figure 5. (A) Western blot of steady-state ATPMS134flag in IPTG-treated samples in DH10B bacteria. Lysates from control cells (lane 1) and a bacterial clone expressing the *Arabidopsis thaliana* PMS134 truncated protein with a FLAG epitope fused to the C-terminus (ATPMS134flag) (lane 2) were electrophoresed on SDS-PAGE gels. Blots were probed with an anti-FLAG monoclonal antibody directed to the FLAG epitope. (B) Number of Kanamycin Resistant ATPMS134flag and vector control DH10B clones. IPTG-induced strains were grown and plated onto AMP and KAN plates and grown for an additional 18 hours at 37°C to identify number of KAN resistant clones due to genetic alteration.

6/6




Figure 6.

Generation of high recombinant producer BGAL-MOR lines in PMS134 expressing DH5alpha host strains. DH5alpha cells containing pTLACZ and TACLACPMS134 were grown with (+) or without (-) IPTG and plated onto LB-Xgal-agar plates. Arrow indicates clones containing pTLACZ and TACLACPMS134 with enhanced β -galactosidase levels *in situ*.